

KSSS 2025

The 42nd International Congress of
Korean Society of Spine Surgery

May 21 (Wed) - 23 (Fri), 2025

Lotte Hotel Seoul (Sogong-dong), Korea

Program Book



**불이 켜졌습니다.
걸어야 할 시간입니다.**

오파몬(Limaprost)은,
요부척추관협착증 환자의
보행거리를 개선합니다.



Limaprost alfadex

Opalmon[®] Tab.
Lumbar Spinal Stenosis

KSSS 2025

C O N T E N T S

Welcome Message	02
Organizing Committee	03
Program at a Glance	12
Scientific Program	13
Venue Information	37
Booth Layout	38
Conference Information	39
Sponsors	44

Welcome Message

Dear distinguished guests, colleagues, and friends,

It is a great honor to welcome you all to the 42nd International Congress of the Korean Society of Spine Surgery (KSSS 2025). As president of this esteemed society, I am privileged to host such a distinguished gathering of spine surgeons from around the world, united by our shared dedication to advancing spinal care and surgery.

KSSS 2025 offers a unique platform for the exchange of cutting-edge knowledge, the sharing of innovative techniques, and collaboration aimed at improving patient outcomes. While spinal surgery has seen remarkable advancements, we continue to face evolving challenges, demanding our commitment to excellence in both clinical practice and research.

I would like to extend my heartfelt gratitude to each of you who have traveled from near and far to be here. Your dedication to advancing the field of spinal surgery is what makes this conference both possible and impactful. I am confident that the discussions and collaborations we will engage in will not only deepen our understanding but also spark new innovations in spinal health.

My special thanks go to our organizing committee, sponsors, and partners, whose hard work and support have brought this event to fruition.

Let us take this opportunity to foster new connections, strengthen existing ones, and collaborate to shape the future of spinal care for the benefit of our patients and our profession.

Once again, welcome, and I look forward to a productive and inspiring conference ahead.

Sincerely,

PARKJB

Jong-Beom Park, MD, PhD
President, Korean Society of Spine Surgery




Organizing Committee

President	Jong-Beom Park
President-elect	Kyung-Soo Suk
Honorary President	Se-Il Suk
Secretary General	Jae Jun Yang
Audit	Young Bae Kim, Chung Hwan Kim
Vice Secretary	Se-Jun Park
Advisory (Past Presidents)	Kwang-Yoon Seo, Byung-Hoon An, Chung-Bin Chu, Kwang-Hoe Kim, Se-Il Suk, Byung-Moon Park, Myung-Sang Moon, Seung-Ho Yoon, Key-Yong Kim, Nam-Hyun Kim, Hong-Tae Kim, Jin-Man Wang, Young-Gu Lee, Ki-Su Kim, Young-Khee Jung, Jae-Rim Cho, Seung-Rim Park, Yung-Tae Kim, Byung Chul Park, June Kyu Lee, Jae Yoon Chung, Heui-Jeon Park, Myun-Whan Ahn, Kee-Yong Ha, Choon-Ki Lee, Jae-Won You, Byung-Joon Shin, Choon Sung Lee, Hwan Mo Lee, Chong-Suh Lee, Ki-Tack Kim, Kyu-Yeol Lee, Whoan Jeang Kim, Chang-Hoon Jeon, Dong-Jun Kim, Hak-Sun Kim, Kyu-Jung Cho, Bong-Soon Chang, Yong Soo Choi, Tae-Kyun Kim
Board of Directors	Chang-Nam Kang, Sang Bum Kim, Seok Woo Kim, Yong-Chan Kim, Jin-Hwan Kim, Tae-Kyun Kim, Woo Dong Nam, Weon Wook Park, Yung Park, Jong-Beom Park, Bo-Gun Suh, Kyung-Soo Suk, Jin Sup Yeom, Dong-Ho Lee, Jung Sub Lee, Jae Chul Lee, Jae Hyup Lee, Soo Taek Lim, Dong Ki Ahn, Kyu-Jung Cho, Yong-Soo Choi
Program & Scientific Committee	CHAIRMAN Jin Sup Yeom DIRECTOR Jiwon Kwon 2nd year Kyung-Chung Kang, Sung-Kyu Kim, Young-Woo Kim, Moon Soo Park, Si-Young Park, Yung Park, Jaewan Soh, Jin Sup Yeom, Ho-Jin Lee, Hae-Dong Jang, Dae-Woong Ham 1st year Jiwon Kwon (Director), Sung-Soo Kim, Young-Yul Kim, Ho-Joong Kim, Dae Jin Nam, Woo-Kie Min, Se-Jun Park, Dong Ki Ahn, Gun Woo Lee, Dong-Ho Lee, Jae-Hyup Lee, Dong-Gune Chang, Nam-Su Chung, Jae-Young Hong
Editorial Committee of Journal of Korean Society of Spine Surgery	CHAIRMAN Si-Young Park DIRECTOR Jae Hyuk Yang 3rd year Ye-Soo Park, Hyoung-Yeon Seo, Kwang-Sup Song, Dong-Eun Shin, Jae Hyuk Yang (Director), Nam-su Chung, Byung-Wan Choi 2nd year Sang-Bong Ko, Sang-Bum Kim, Young-Hoon Kim, Hyoung-Min Kim, Woo-Dong Nam, Woo-Kie Min, Jae-Jun Yang, Bong-Soon Chang 1st year Tae-Kyun Kim, Si-Young Park, Hyun-Jin Park, Chang-Hwa Hong, Chang-Ju Hwang

Editorial Committee of Asian Spine Journal	CHAIRMAN	Hak-Sun Kim	DIRECTOR	Jae Hwan Cho
	3rd year	Sung-Soo Kim, Kun-Bo Park, Jae-Chul Lee, Jae Hwan Cho (Director)		
	2nd year	Sang Il Kim, Sung-Kyu Kim, Ho-Joong Kim, Sang-Min Park, Hyung-Youl Park, Gun Woo Lee, Byung Ho Lee, Dong-Gune Chang, Sam Yeol Chang, Hae-Dong Jang, Sung Hoon Choi		
	1st year	Jiwon Kwon, Hak-Sun Kim, Se-Jun Park, Sehan Park, Jin Sung Park		
Insurance Committee	CHAIRMAN	Chang Hwa Hong	DIRECTOR	Han-Dong Lee
	2nd year	Min-Seok Kim, Jung-Hoon Kim, Jin-Hwan Kim, Ki Se Nam, Woo Dong Nam, Se Jun Park, Si Young Park, Yung Park, Dong Eun Shin, Hun Kyu Shin, Dong Ki Ahn, Jeong Hyun Yoo, Byung Ho Lee, Jun-Seok Lee, Sang-Bum Chang, Hae-Dong Jang, Sung Hoon Choi, Yong-Gi Choi, Chang Hwa Hong		
	1st year	Kyu Bok Kang, Chang-Nam Kang, Yong-Chan Kim, Ho-Joong Kim, Hyun-Jin Park, Seung-Pyo Suh, Seung-Deok Sun, Jae Jun Yang, Jae Ho Yang, Han-Dong Lee (Director), Ho-Jin Lee, Taek Soo Jeon		
Bylaws Committee	CHAIRMAN	Kyu-Jung Cho	SECRETARY	Jae Jun Yang
		Si Young Park, Jong-Beom Park (President), Kyung-Soo Suk, Jae Jun Yang (Secretary), Jae Chul Lee, Kyu-Jung Cho		
Website Committee	CHAIRMAN	Jae Chul Lee	SECRETARY	Chang Ju Hwang
	2nd year	Young Bae Kim, Hyoung Min Kim, Sang-Min Park, Kee-Won Rhyu, Jae Chul Lee, Sam Yeol Chang, Sung Hoon Choi, Chang Ju Hwang (Secretary)		
	1st year	Young-Woo Kim, Yong-Chan Kim, Kun-Woo Park, Kun Young Park, Jaewan Soh, Kwang-Sup Song, Joong hyun Ahn, Jae-Young Hong		
Public Relations Committee	CHAIRMAN	Kyung-Chung Kang	DIRECTOR	Sub-Ri Park
	2nd year	Kyung-Chung Kang, Kyoung-Hwan Kim, Han-Dong Lee, Hyung-Rae Lee		
	1st year	Jong-Hyun Ko, Sang Bum Kim, Dae Jin Nam, Sub-Ri Park (Director), Jae Jin Park, Ji-Won Park, Hyun-Jin Park, Hee Jung Son, Jae-Won Shin, Ki-Young Lee, Soo-Bin Lee		
Board of Education	CHAIRMAN	Jae Hyup Lee	DIRECTOR	Ho-Jin Lee
		Jong-Hyun Ko, Sung-Kyu Kim, Yong-Chan Kim, Ho-Joong Kim, Woo-Kie Min, Se-Jun Park, Ji-Won Park, Hyung-Youl Park, Dong-Ho Lee, Byung Ho Lee, Jae Hyup Lee (Chairman), Han-Dong Lee, Ho-Jin Lee (Director), Nam-Su Chung, Chang Ju Hwang		
Finance Committee	CHAIRMAN	Jong-Beom Park	SECRETARY	Jae Jun Yang
		Tae-Kyun Kim, Whoan-Jeang Kim, Se-Jun Park, Jong-Beom Park (President), Kyung-Soo Suk, Jae Jun Yang (Secretary), Kee-Won Rhyu, Young-Khee Chung		

PYXIS™

3D Printing Titanium OLIF Cage



New Neuropathic Pain Agent



NEW NEUROPATHIC PAIN AGENT



NEUCOURSE ¹

an Asian, phase 3, multicenter, randomized, double-blind, placebo-controlled 14-week study of mirogabalin in patients with postherpetic neuralgia followed by a 52-week open-label extension

REDUCER ²

an Asian, phase3, multicenter, **R**andomiz**E**d,
Double-blind, placebo-controlled 14-week
st**U**dy of mirogabalin in patients with diabeti**C**
p**E**ripheral neu**R**opathic pain,

1. Kato, Jitsu, et al. "Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients." *Pain* 160.5 (2019): 1175.

2. Baba, Masayuki, et al. "Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind placebo-controlled phase III study in Asian patients." *Journal of diabetes investigation* 10.5 (2019): 1299-1306.

P23-090-2025.04-V1

PREScribing INFORMATION

[illegible]

수입판매원



한국다이어찌산교주식회사

Daiichi-Sankyo 서울시 중구 을지로5길 26 미래에셋 센터원빌딩 동관 15층 Tel. 02-3453-3300

Stay Strong with Stoboclo[®]

Strong Bones, Stronger You

스토보클로프리필드시린지(데노수맵) 제품정보

[효능·효과] 1. 폐경 후 여성 골다공증 환자의 치료 2. 남성 골다공증 환자의 골밀도 증가를 위한 치료 3. 글루코코르티코이드 유발성 골다공증의 치료 4. 안드로겐 차단요법을 받고 있는 비전이성 전립선암 환자의 골 소실 치료 5. 아로마타제 억제제 보조요법을 받고 있는 여성 유방암 환자의 골 소실 치료 **[용법·용량]** 이 약은 보건의로 전문가에 의해 투여되어야 한다. 이 약 1시린지(데노수맵 60 mg)를 매 6개월마다 상완, 허벅지 위쪽 또는 복부에 피하 주사한다. 모든 환자는 칼슘 1000 mg과 비타민D 400 IU 이상을 매일 복용해야 한다. 정기 투여일에 이 약을 투여하지 못했을 경우, 가능한 빨리 투여한다. 그 후, 마지막 투여일로부터 매 6개월마다 투여한다.



스토보클로프리필드시린지(데노수맵) 제품정보

자세한 제품 정보 확인을 위해 QR code로 연결된 제품 설명서를 참고하여 주시기 바랍니다.

Innovative Solutions with **NOVOGRID Biopatch**

100% dermis with CGBIO's manufacturing technology
No wash out, Zero-waste Adhesion Barrier



NOVOGRID



- ✓ Safety
- ✓ Usability
- ✓ Biocompatibility

CGBIO
CELL & GROWTH FACTOR
BIOTECHNOLOGY

BUILD NEW BONES WITH EVENITY®

최근 골절이 있거나 골밀도가 매우 낮은 골다공증 환자는
이베니티®로 치료 시작해 주세요!¹⁻³



이중 효과의 작용기전⁴⁻⁶

이베니티®는 골형성을 촉진하고 골흡수를 감소시키는
최초이자 유일한* 이중기전의 골다공증 치료제입니다.

*2023년 1월 기준



골절 감소 효과^{4,7}

약 12,000명의 PMO 환자가
3상 임상에 참여하였습니다.



1달에 1번, 12회⁴

이베니티®는 1달에 1번 투여로 간편하며,
단 12개월만에 치료 효과¹를 입증하였습니다.

¹골절 위험 감소, 골밀도 증가, 골 강도 향상 등

EVENITY®
(romosozumab-aqqg)
injection 105 mg/1.17 mL

prolia®
(denosumab)injection

PMO, postmenopausal osteoporosis.

References 1. Camacho PM, et al. *Endocr Pract.* 2020;26(Suppl 1):1-46. 2. Shoback D, et al. *J Clin Endocrinol Metab.* 2020;105(3):587-594. 3. Eastell R, et al. *J Clin Endocrinol Metab.* 2019;104(5):1595-1622. 4. 식품의약품안전처 의약품통합정보시스템. 의약품제품정보 상세보기_이베니티주프라임드시란지(로모소주맙, 유전자재조합) Accessed on 2023-01-09. 5. Food and Drug Administration. Teriparatide prescribing information. 6. Food and Drug Administration. Abaloparatide prescribing information. 7. Langdahl BL, et al. *Lancet.* 2017;390:1585-1594.



Product Information

처방하시기 전 QR 코드 또는 식품의약품안전처 의약품통합정보시스템(<https://nedrug.mfds.go.kr>)을 통해 상세 제품정보를 참조하시기 바랍니다.

AMGEN

암젠코리아유한회사

서울특별시 중구 을지로5길 19, 20층 Tel. 02-3434-4899



중 근 당

공동판매원 중근당주식회사

서울특별시 서대문구 중정로 8 (충정로 37) TEL 02-2194-0300 FAX 02-2194-0369

소비자상담실 : 080-6776-080 (수신자부담) 제품상세정보 : www.ckdpharm.com 참조

The World's First Combination of SERM+Vitamin D

Rabone **D** Cap. (Raloxifene / Cholecalciferol)



Treatment and Prevention of Osteoporosis in Postmenopausal Women

- Long-term prescription without drug holiday by taking 1 capsule orally once daily¹⁾
- Decrease the risk of vertebral fractures in patients with postmenopausal osteoporosis, due to its ability of slowing the accelerated bone turnover to premenopausal ranges²⁾
- Vitamin D can be taken at the price of Raloxifene as a single drug

[Indications and Usage] Treatment and prevention of osteoporosis in postmenopausal women [Dosage and Administration] 1 capsule orally once daily

※Refer to the attached document for detailed us

The cited data are not the result of direct administration of Hanmi Pharmaceutical products.

SERM : selective estrogen receptor modulator.

Reference. 1) Korean Society for Bone and Mineral Research, Physician's Guide for Osteoporosis 2022. 2) Rey JR, Cervino EV, Rentero ML, et al. Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. *Open Orthop J*. 2009;3:14-21.



The Korean Society of Spine Surgery



SUBSCRIBE
To Keep Updated



대한척추외과학회 | 신경차단술 동의서 읽어주는 척추정형외과 의사
조회수 4회 · 9분 전



대한척추외과학회 | 신경차단술의 모든 것
조회수 63회 · 2주 전



대한척추외과학회 | 허리 시술의 모든 것
조회수 77회 · 3주 전



대한척추외과학회 | 주사치료의 모든 것
조회수 116회 · 1개월 전



대한척추외과학회 | 크런치, 이렇게만 하면 된다?! 목척추운동 5편!
조회수 2.8천회 · 6개월 전



대한척추외과학회 | 목 건강을 지키는 스트레칭, 따라해보세요! 목척추운동 4편!
조회수 1.7천회 · 6개월 전



대한척추외과학회 | 턱걸이, 이렇게만 하면 된다?! 목척추운동 3편!
조회수 1.8천회 · 6개월 전



대한척추외과학회 | 스쿼트, 이렇게만 하면 된다?! 목척추운동 2편!
조회수 1.8천회 · 6개월 전



대한척추외과학회 | 데드리프트, 이렇게만 하면 된다?! 목척추운동 1편!
조회수 1.5천회 · 7개월 전



대한척추외과학회 40주년 -척추 건강을 선도한 여정-
조회수 353회 · 11개월 전



대한척추외과학회 | 필라테스를 잘못하면 독이 된다?! 필라테스 4편!
조회수 1.3천회 · 1년 전



대한척추외과학회 | 척추측만증이 있어도 필라테스 할 수 있나요? 필라테스 3편!
조회수 8.1천회 · 1년 전

Program at a Glance

May 21 (Wed)

Time	36F
14:00 - 17:00	KSSS 2025 Basic Research Symposium (Belle-Vue Suite 36F)
17:00 - 17:10	Group Photo (Belle-Vue Suite 36F)
17:10 - 18:10	Cocktail Reception (Charlotte Suite 36F) Presidential Roundtable Meeting (Astor Suite 36F)
18:10 - 20:10	Welcome Reception (Belle-Vue Suite 36F)

May 22 (Thu)

Time	Crystal Ballroom A	Crystal Ballroom B
07:10 - 07:40	Breakfast Symposium I	Breakfast Symposium II
07:50 - 08:00	Opening Remarks (Crystal Ballroom A+B)	
08:00 - 08:30	Cervical (1)	Basic Research (1)
08:30 - 09:00	Cervical (2)	Basic Research (2)
09:00 - 09:30	Cervical (3)	Deformity (1)
09:30 - 09:50	Invited Lecture I	Invited Lecture II
09:50 - 10:10	Coffee Break	
10:10 - 11:00	Plenary Lecture I (Crystal Ballroom A)	
11:00 - 12:00	Asian Spine Society Session I	Asian Spine Society Session II
12:00 - 13:00	Luncheon Symposium I	Luncheon Symposium II
13:00 - 14:00	Symposium I: Cervical	Symposium II: Deformity
14:00 - 14:20	Invited Lecture III	Invited Lecture IV
14:20 - 14:40	Coffee Break	
14:40 - 15:10	Lumbar (1)	Deformity (2)
15:10 - 15:40	Lumbar (2)	Deformity (3)
15:40 - 16:10	Lumbar (3)	Deformity (4)
16:10 - 16:40	KSSS Research Award (Crystal Ballroom A)	
16:40 - 17:10	KSSS General Assembly (Crystal Ballroom A)	
17:10 - 17:20	Group Photo (Crystal Ballroom A)	
17:20 - 18:20	Cocktail Reception (Exhibition Hall, 2F)	
18:20 - 20:20	Gala Dinner (Crystal Ballroom A+B)	

May 23 (Fri)

Time	Crystal Ballroom A	Crystal Ballroom B
07:20 - 07:50	Breakfast Symposium III	Breakfast Symposium IV
08:00 - 08:30	Best Paper Candidates Presentation I (Domestic)	Lumbar (4)
08:30 - 09:00	Best Paper Candidates Presentation II (Domestic)	MIS (1)
09:00 - 09:30	Best Paper Candidates Presentation III (Domestic)	MIS (2)
09:30 - 10:00	Best Paper Candidates Presentation IV (International)	MIS (3)
10:00 - 10:20	Coffee Break	
10:20 - 11:10	Plenary Lecture II (Crystal Ballroom A)	
11:10 - 11:30	Invited Lecture V	Invited Lecture VI
11:30 - 12:00	Best Paper Candidates Presentation V (International)	MIS (4)
12:00 - 12:30	Best Paper Candidates Presentation VI (International)	Tumor
12:30 - 13:30	Luncheon Symposium III	Luncheon Symposium IV
13:30 - 14:30	Symposium III: Lumbar	Symposium IV: MIS
14:30 - 14:50	Invited lecture VII	Invited lecture VIII
14:50 - 15:10	Coffee Break	
15:10 - 15:40	Deformity (5)	Trauma
15:40 - 16:10	Infection	Miscellaneous
16:10 - 16:50	Asian Spine Society Traveling Fellowship & Visiting Reports (Crystal Ballroom A)	
16:50 - 17:10	Best Paper Awards (Crystal Ballroom A)	
17:10 - 17:20	Closing Remarks (Crystal Ballroom A)	
17:20 - 17:30	Farewell and Inauguration Ceremony for the President of KSSS (Crystal Ballroom A)	

Scientific Program

May 21 (Wed)		Belle-Vue Suite (36F)
14:00 - 14:05	Opening Remarks by the President of the Korean Society of Spine Surgery (KSSS)	Jong-Beom Park (Korea)
14:05 - 14:10	Welcome Address by the President of the Korean Basic Research Society of Spine	Woo-Kie Min (Korea)
14:10 - 15:25	Basic Research Symposium: Session 1	Jin Hwan Kim (Korea) Jae-Hyup Lee (Korea)
14:10 - 14:25	S001 Replicative Lifespan and Senescence of Disc Cells, and Directions of Regeneration Research	Jun-Seok Lee (Korea)
14:25 - 14:40	S002 Biomechanical Effects of Cement Augmentation and Prophylactic Vertebroplasty Adjacent Segment Stability in Multilevel Spinal Fusion Finite Element Analysis	Byung Ho Lee (Korea)
14:40 - 14:55	S003 Introduction of AI in Spine and CT-Based AI for Detection of Spinal Fractures	Han-Dong Lee (Korea)
14:55 - 15:10	S004 Recent Biological Studies in Osteoporosis Treatment	Sehan Park (Korea)
15:10 - 15:25	Discussion	
15:25 - 15:45	Coffee Break	
15:45 - 17:00	Basic Research Symposium: Session 2	Yong-Soo Choi (Korea) Woo-Kie Min (Korea)
15:45 - 16:05	S005 Osteobiologics - The Need for Evidence!	Sangwook Tim Yoon (USA)
16:05 - 16:25	S006 Code Spinal Cord Injury: Laboratory to Clinical Practice	Kee D. Kim (USA)
16:25 - 16:45	S007 Artificial Intelligence in Spine Surgery and Research	Wongthawat Liawrungrueang (Thailand)
16:45 - 17:00	Discussion	
17:00 - 17:10	Closing & Group Photo (Belle-Vue Suite 36F)	
17:10 - 18:10	Cocktail Reception (Charlotte Suite 36F) / Presidential Roundtable Meeting (Astor Suite 36F)	
18:10 - 20:10	Welcome Reception (Belle-Vue Suite 36F)	

Scientific Program

P : Podium No.

May 22 (Thu)		Crystal Ballroom A (2F)
07:10 - 07:40	Breakfast Symposium I	Jae-Young Hong (Korea)
07:10 - 07:25	[Sponsored by Medtronic Korea]  P1 Anterior vs. Posterior Fusion Surgery for Cervical Spondylotic Myelopathy Patients with Segmental Instability	Jiwon Park (Korea)
07:25 - 07:40	[Sponsored by Viatrix Korea]  P1 Multi-Modal Pain Management Within an Enhanced Recovery Program After Surgery	Sehan Park (Korea)
07:50 - 08:00	Opening Remarks (Crystal Ballroom A+B)	Jong-Beom Park (President of KSSS)
08:00 - 08:30	Cervical (1)	Young-Sang Lee (Korea) Kyung-Chung Kang (Korea)
08:00 - 08:05	P1 S008 Elderly Specific Characteristics of Preoperative Presentation and Postoperative Course of Cervical Myelopathy Patients Treated with Laminoplasty	Sehan Park (Korea)
08:05 - 08:10	P2 S009 Comparative Study on Revision Rate After ACDF or ADR: A Review of Korean Healthcare Data	Junghyun Oh (Korea)
08:10 - 08:15	P1 S010 Distinct Clinical Characteristics in the Thoracic Versus Cervical Ossification of the Posterior Longitudinal Ligament	Kihyun Kwon (Korea)
08:15 - 08:20	P2 S011 The Value of Treatment Guidance by Facet Fluid Effusion Found on MRI in Patients with Cervical Degenerative Spondylolisthesis	Howard, Hao-wen Chen (Taiwan)
08:20 - 08:30	Discussion	
08:30 - 09:00	Cervical (2)	Bo-Gun Suh (Korea) Hyoungmin Kim (Korea)
08:30 - 08:35	P1 S012 Biomechanical Analysis Comparison of Different Cervical Posterior Fixation Techniques: A Finite Element Study	Wooseok Jung (Korea)
08:35 - 08:40	P2 S013 Precision in Cervical Spine Surgery: A Systematic Review and Network Meta-Analysis of Navigated Guides for Safe and Effective Pedicle Screw Fixation	Peem Sarasombath (Thailand)
08:40 - 08:45	P1 S014 Comparison of Topical Methylprednisolone 40 vs 80 mg on Postoperative Dysphagia After Multilevel ACDF: A Randomized, Doubleblinded, Controlled Trial	Natcha Chutchomchuen (Thailand)

Scientific Program

P : Podium No.

May 22 (Thu)		Crystal Ballroom A (2F)
08:45 - 08:50	P2 S015 Postoperative Motor Recovery in Patients with Degenerative Cervical Spondylosis and Severe Muscle Weakness: Analysis of Drop Arm and Drop Finger Cases	Masahito Oshina (<i>Japan</i>)
08:50 - 09:00	Discussion	
09:00 - 09:30	Cervical (3)	Moon Soo Park (<i>Korea</i>) Byung Wan Choi (<i>Korea</i>)
09:00 - 09:05	P1 S016 Radiculopathy Patients Experience Greater Gains Despite Worse Preoperative Status Compared to Myelopathy: Evaluating Prognostic Factors for Successful in ACDF	Jiwon Park (<i>Korea</i>)
09:05 - 09:10	P2 S017 Is the Formation of Interlaminar Fusion Mass Significant in the Surgical Outcomes of Posterior C1-2 Screw Fixation and Fusion?	Gumin Jeong (<i>Korea</i>)
09:10 - 09:15	P1 S018 Clinicoradiological Outcome of Surgical Treatment of Cervicothoracic Junction Tuberculosis: A 10-Year Retrospective Study	Tej Prakash Dawadi (<i>Nepal</i>)
09:15 - 09:20	P2 S019 Surgical Outcome of ACDF with Total Uncinectomy for Proximal Type of Cervical Spondylotic Amyotrophy	Woo-Kie Min (<i>Korea</i>)
09:20 - 09:30	Discussion	
09:30 - 09:50	Invited Lecture I	Kyu Jung Cho (<i>Korea</i>)
09:30 - 09:45	P1 S020 Looking Back on 10 Years of Adult Spinal Deformity Surgical Treatment -How to Prevent Complication-	Yukihiro Matsuyama (<i>Japan</i>)
09:45 - 09:50	Discussion	
09:50 - 10:10	Coffee Break	
10:10 - 11:00	Plenary Lecture I	Jong-Beom Park (<i>Korea</i>)
10:10 - 10:30	P1 S021 Treatment Strategy for Spinal Cord Tumors	Masaya Nakamura (<i>Japan</i>)
10:30 - 10:50	P1 S022 Regenerative Medicine of Spinal Cord Injury Using iPS Cells	Masaya Nakamura (<i>Japan</i>)
10:50 - 11:00	Discussion	
11:00 - 12:00	Asian Spine Society Session I	Tae-Kyun Kim (<i>Korea</i>)
11:00 - 11:12	P1 S023 Cervical Pott's Disease	Andra Hendriarto (<i>Indonesia</i>)
11:12 - 11:15	Discussion	

Scientific Program

P : Podium No.

May 22 (Thu)		Crystal Ballroom A (2F)
11:15 - 11:27	P1 S024 The Role of Traditional Growing Rods (TGR) in the Management of Early Onset Scoliosis	Chris Chan Yin Wei (<i>Malaysia</i>)
11:27 - 11:30	Discussion	
11:30 - 11:42	P1 S025 Modified Cortical Bone Trajectory for Thoraco-lumbar Spine Fixation: Clinical Implications and Feasibility	Dipak Shrestha (<i>Nepal</i>)
11:42 - 11:45	Discussion	
11:45 - 11:57	P1 S026 OLIF in NO Corridor, Possible or Not	Worawat Limthongkul (<i>Thailand</i>)
11:57 - 12:00	Discussion	
12:00 - 13:00	Luncheon Symposium I	Tae-Kyun Kim (<i>Korea</i>)
12:00 - 12:30	[Sponsored by Dong-A ST]  DONG-A ST Evidence for Limaprost in the Treatment of Lumbar Spinal Stenosis	Hyung-Youl Park (<i>Korea</i>)
12:30 - 13:00	[Sponsored by Daewon Pharmaceutical] daewon Pharmaceutical Management of Spinal Pain: Combined Therapy	Tae-Hoon Kim (<i>Korea</i>)
13:00 - 14:00	Symposium (I) Cervical: Current Trends in Degenerative Cervical Myelopathy	Kyung-Soo Suk (<i>Korea</i>) Jae Jun Yang (<i>Korea</i>)
13:00 - 13:09	P1 S027 Clinical Assessment and DDx. of Cervical Myelopathy	Han-Dong Lee (<i>Korea</i>)
13:09 - 13:18	P2 S028 Combined Radiculopathy in Cervical Myelopathy	Sehan Park (<i>Korea</i>)
13:18 - 13:27	P1 S029 Mild Cervical Myelopathy: Observation or Do Operation?	Byung Wan Choi (<i>Korea</i>)
13:27 - 13:36	P2 S030 Diagnosis of Osteoporotic Spinal Fractures	Jiwon Park (<i>Korea</i>)
13:36 - 13:45	P1 S031 Surgical Strategy in Mild Kyphosis	Kyung-Chung Kang (<i>Korea</i>)
13:45 - 14:00	Discussion	
14:00 - 14:20	Invited Lecture III	Jin Sup Yeom (<i>Korea</i>)
14:00 - 14:15	P1 S032 Cervical Spine Injury in Spinal Ankylosing Disorders	Wen-Tien Wu (<i>Taiwan</i>)
14:15 - 14:20	Discussion	
14:20 - 14:40	Coffee Break	

Scientific Program

P : Podium No.

May 22 (Thu)		Crystal Ballroom A (2F)
14:40 - 15:10	Lumbar (1)	Yong Chan Kim (Korea) Tae-Hoon Kim (Korea)
14:40 - 14:45	P1 S033 Sacroiliac Joint Degeneration Following Lumbar Fusion: The Influence of Pelvic Mechanics and Spino-Pelvic Alignment	Wooseok Jung (Korea)
14:45 - 14:50	P2 S034 Modified Open TLIF with Contralateral Facet Fusion vs. Conventional Open PLIF: A Retrospective Case-Control Study on Fusion Rates and Clinical Outcomes at 1-Year Follow-Up	Seok-In Jang (Korea)
14:50 - 14:55	P1 S035 Adjacent Segment Degeneration in Single Level Transforaminal Lumbar Interbody Fusion: Comparative Study Between Expandable Versus Static Cages	Wai Him Lam (Hong Kong)
14:55 - 15:00	P2 S036 Duration of Aggravated Symptoms Can Affect Satisfaction After Degenerative Lumbar Surgery	Kihyun Kwon (Korea)
15:00 - 15:10	Discussion	
15:10 - 15:40	Lumbar (2)	Chang-Hwa Hong (Korea) Kun Young Park (Korea)
15:10 - 15:15	P1 S037 Dynamic Interspinous Radiology as a Predictor for Early-Onset Adjacent Segment Degeneration After Multilevel Lumbar Interbody Fusion (L2-ilium)	Xiongjie Li (China)
15:15 - 15:20	P2 S038 Trans-Pedicular Intravertebral Cage Augmentation (TPICA) with Short-Level Fixation in the Treatment of Kummell Disease: Mid-Term Results from a Case Series	Dae-Woong Ham (Korea)
15:20 - 15:25	P1 S039 The Effect of Obesity on Post Surgical Complication in Patients with Degenerative Spondylolisthesis Spectrum: A Meta-Analysis	Andino Zavtra (Indonesia)
15:25 - 15:30	P2 S040 Anti-Osteoporosis Medication in Patients with Posterior Spine Fusion: A Systematic Review and Meta-Analysis	HyungSub Jin (Korea)
15:30 - 15:40	Discussion	
15:40 - 16:10	Lumbar (3)	Dong-Eun Shin (Korea) Jae Ryong Cha (Korea)
15:40 - 15:45	P1 S041 Expandable and Static Cages in Posterior Lumbar Interbody Fusion in Patients with High Risk Factors for Subsidence	Jeuk Lee (Korea)
15:45 - 15:50	P2 S042 Inferior Clinical and Functional Outcomes in Revision Versus Primary Transforaminal Lumbar Interbody Fusion	Weon Min Cho (Korea)

Scientific Program

P : Podium No.

May 22 (Thu)		Crystal Ballroom A (2F)
15:50 - 15:55	P1	S043 Indirect Decompression Lateral Lumbar Interbody Fusion Risk Score (ID-LLIF Risk Score System) to Predict Successful Indirect Decompression in Lateral Lumbar Inter Body Fusion Narat Virojanawat (<i>Thailand</i>)
15:55 - 16:00	P2	S044 Unilateral Laminotomy and Bilateral Decompression (ULBD) for Lumbar Spine Stenosis (LSS): An Early Experience at Eastern Nepal Prem Bahadur Shahi (<i>Nepal</i>)
16:00 - 16:10		Discussion
16:10 - 16:40		KSSS Research Award (Crystal Ballroom A)
16:10 - 16:25		KSSS Dong-A Research Award
16:10 - 16:18		Presentation
16:18 - 16:25		Discussion
16:25 - 16:40		KSSS Daewon Research Award
16:25 - 16:33		Presentation
16:33 - 16:40		Discussion
16:40 - 17:10		KSSS General Assembly (Crystal Ballroom A)
17:10 - 17:20		Group Photo (Crystal Ballroom A)
17:20 - 18:20		Cocktail Reception (Exhibition Hall, 2F)
18:20 - 20:20		Gala Dinner (Crystal Ballroom A+B)

Scientific Program

P : Podium No.

May 22 (Thu)		Crystal Ballroom B (2F)
07:10 - 07:40	Breakfast Symposium II	Kyung-Chung Kang (Korea)
07:10 - 07:25	P3 [Sponsored by HK inno.N] inno.N Innovate Now & Next Postoperative Pain Management	Han-Dong Lee (Korea)
07:25 - 07:40	P3 [Sponsored by Dalim Medical] dalim medical Hemostatic Efficacy and Safety of CollaStat® in a Spinal Surgery	Jaewon Shin (Korea)
07:50 - 08:00	Opening Remarks (Crystal Ballroom A+B)	Jong-Beom Park (President of KSSS)
08:00 - 08:30	Basic Research (1)	Woo-Kie Min (Korea) Young-Yul Kim (Korea)
08:00 - 08:05	P3 S045 Discordance Between Anatomical Nerve Root Compression and EMG Findings in Patients with S1 Lumbarization or L5 Sacralization	Yunjin Nam (Korea)
08:05 - 08:10	P4 S046 Enriched Peripheral Blood-Derived Mononuclear Cells for Treating Intervertebral Disc Degeneration	Yu-Hsuan Chung (Taiwan)
08:10 - 08:15	P3 S047 Development of an AI-Based Object Detection Model for Spine Endoscopic Surgery Using Spine Scope Videos	Yoon Jae Cho (Korea)
08:15 - 08:20	P4 S048 AI-Based Analysis Highlights the Critical Role of Erector Spinae Muscle Health in Predicting Outcomes After Lumbar Spinal Fusion	Namhoo Kim (Korea)
08:20 - 08:30	Discussion	
08:30 - 09:00	Basic Research (2)	Jae Hyuk Shin (Korea) Junseok Lee (Korea)
08:30 - 08:35	P3 S049 Efficacy of Deep Neural Networks for Automatic Detection of Traumatic Cervical Spinal Fractures on CT Scans	Han-Dong Lee (Korea)
08:35 - 08:40	P4 S050 Design and Biomechanical Analysis of Stand-Alone Lumbar Cage Implant for Posterior Interbody Fusion	Sudhir Ganesan (India)
08:40 - 08:45	P3 S051 Feasibility of Lumbopelvic Muscles Volume for Estimating Total Muscle Volume on Computed Tomography: AI-Based Automatic Image Analysis	Minsuk Kim (Korea)
08:45 - 08:50	P4 S052 Biomechanical Effects of Cement Augmentation and Prophylactic Vertebroplasty on Adjacent Segment Stability in Multilevel Spinal Fusion: Finite Element Analysis	Jaewon Shin (Korea)
08:50 - 09:00	Discussion	

Scientific Program

P : Podium No.

May 22 (Thu)		Crystal Ballroom B (2F)
09:00 - 09:30	Deformity (1)	Seung-Woo Suh (Korea) Sung-Soo Kim (Korea)
09:00 - 09:05	P3 S053 Neurofibroma Subtypes and Spinal Dural Ectasia: Key Factors Driving Rapid Scoliosis Progression in Neurofibromatosis Type 1 on Whole-Body Magnetic Resonance Imaging	Ji Uk Choi (Korea)
09:05 - 09:10	P4 S054 Incidence of Intraspinous Pathology in Patients with Early Onset Scoliosis. A Malaysian Public Tertiary Referral Centre Experience	Harkeerat Singh A/L Sukhdarshan Singh (Malaysia)
09:10 - 09:15	P3 S055 Association of Scoliotic Shoulder Imbalance and Its Post-Operative Correction with Lenke Classification	Mubashar Ahmed Bajwa (Pakistan)
09:15 - 09:20	P4 S056 Predicting Postoperative Coronal Trunk Shift in Adolescent Idiopathic Scoliosis Surgery Using Intraoperative Crossbar Measurement Technique	Suttinont Surapuchong (Thailand)
09:20 - 09:30	Discussion	
09:30 - 09:50	Invited Lecture II	BongSoon Chang (Korea)
09:30 - 09:45	P3 S057 Craniovertebral Junction Deformity: Its Evaluation and Surgical Planning	Sudhir Kumar Srivastava (India)
09:45 - 09:50	Discussion	
09:50 - 10:10	Coffee Break	
10:10 - 11:00	Plenary Lecture I (Crystal Ballroom A)	Jong-Beom Park (Korea)
11:00 - 12:00	Asian Spine Society Session II	Yong-Soo Choi (Korea)
11:00 - 11:12	P3 S058 Interpretation of Signal Loss in Intra Operative Neuromonitoring	Ronald P. Tangente (Philippines)
11:12 - 11:15	Discussion	
11:15 - 11:27	P3 S059 Advancements in Full Endoscopic Spine Surgery: Trends and Clinical Insights	Wongthawat Liawrungrueang (Thailand)
11:27 - 11:30	Discussion	
11:30 - 11:42	P3 S060 Beyond the Hunch: Navigating the Landscape of Post TB - Kyphosis	Shah Alam (Bangladesh)
11:42 - 11:45	Discussion	

Scientific Program

P : Podium No.

May 22 (Thu)		Crystal Ballroom B (2F)
11:45 - 11:57	P3 S061 Myanmar Experience of Upper Cervical Spine Problems	Thant Zin Naing (Myanmar)
11:57 - 12:00	Discussion	
12:00 - 13:00	Luncheon Symposium II	Jong-Beom Park (Korea)
12:00 - 12:30	[Sponsored by GS Medical]  P3 S061 Pushing the Limits of Posterior Cervical Instrumentation: Surgical Solutions for Extreme Cases	Hyoungmin Kim (Korea)
12:30 - 13:00	[Sponsored by Daewoong Pharmaceutical]  P3 The New Era of Osteoporosis Treatment with Denosumab (STOBOCLO)	Se-Jun Park (Korea)
13:00 - 14:00	Symposium (II) Deformity: Updates for Adult Spine Deformity (ASD) Decision Making	Hak-Sun Kim (Korea) Dong Soo Kim (Korea)
13:00 - 13:12	P3 S062 Perioperative Medical Optimizations for ASD	Nam-Su Chung (Korea)
13:12 - 13:24	P4 S063 Determination of Upper Instrumented Vertebra in Adult Spinal Deformity	Jae Hyuk Yang (Korea)
13:24 - 13:36	P3 S064 Usefulness of Lateral Lumbar Interbody Fusion in Adult Spinal Deformity	Dong-Gune Chang (Korea)
13:36 - 13:48	P4 S065 How to Minimize Mechanical Complications After Adult Spinal Deformity Correction	Joonghyun Ahn (Korea)
13:48 - 14:00	Discussion	
14:00 - 14:20	Invited Lecture IV	Hak-Sun Kim (Korea)
14:00 - 14:15	P3 S066 Scoliosis Surgery for AIS Patients with Major Lumbar Curves: Preventing Post-operative Truncal Imbalance and Limb Length Discrepancy	Mun Keong Kwan (APSS)
14:15 - 14:20	Discussion	
14:20 - 14:40	Coffee Break	
14:40 - 15:10	Deformity (2)	Chang Ju Hwang (Korea) Kun Bo Park (Korea)
14:40 - 14:45	P3 S067 Determination of LIV in Single Thoracic Idiopathic Scoliosis: Feasibility of Prone Radiographs	Gumin Jeong (Korea)

Scientific Program

P : Podium No.

May 22 (Thu)		Crystal Ballroom B (2F)
14:45 - 14:50	P4 S068 Radiation Free Screening of Scoliosis Using Artificial Intelligence and Machine Learning	Arpit Sahu (India)
14:50 - 14:55	P3 S069 Predicting Necessity of Operation for Adolescent Idiopathic Scoliosis After Brace Application	Youngtak Yu (Korea)
14:55 - 15:00	P4 S070 Spinal Deformity in Osteogenesis Imperfecta: A Filipino Patient's Journey in Corrective Surgical Management	Paul Julius Aguiro Medina (Philippines)
15:00 - 15:10	Discussion	
15:10 - 15:40	Deformity (3)	Young-Hoon Kim (Korea) Hojoong Kim (Korea)
15:10 - 15:15	P3 S071 Revision Surgery for Adult Spinal Deformity with Postsurgical Flatback Deformity: Lateral Lumbar Interbody Fusion with Posterior Column Osteotomy Versus 3-Column Osteotomy	Ki Young Lee (Korea)
15:15 - 15:20	P4 S072 T10-Pelvic Angle as a Newly Introduced Sagittal Parameter: Validation Study in Terms of Pelvic Tilt Restoration, Proximal Junctional Kyphosis, and Clinical Outcomes in Adult Spinal Deformity Surgery	Hyun-Jun Kim (Korea)
15:20 - 15:25	P3 S073 The Risk Factors for Mechanical Complications After Deformity Correction in Patients with Degenerative Lumbar Scoliosis Combined with Sagittal Imbalance	Sung-Min Kim (Korea)
15:25 - 15:30	P4 S074 A Novel Easy-to-Measure Radiographic Parameter to Assess Spinopelvic Malalignment: The Pelvic Inclination Angle (PIA)	Yunjin Nam (Korea)
15:30 - 15:40	Discussion	
15:40 - 16:10	Deformity (4)	Jung-Hee Lee (Korea) Dong-Gune Chang (Korea)
15:40 - 15:45	P3 S075 The Relationship Between Failure of Pelvic Restoration and Hamstring Tightness After Adult Spine Deformity Surgery	Seok-In Jang (Korea)
15:45 - 15:50	P4 S076 Different Characteristics Between Acute and Delayed Proximal Junctional Failure in Elderly Patients Undergoing Corrective Surgery for Adult Spinal Deformity: Comparative Analysis of Risk Factor, Failure Mode, and Clinical Consequences	Se-Jun Park (Korea)
15:50 - 15:55	P3 S077 Strategies for Managing Post-Surgical Deformities in Spine Surgery	Yuching Huang (Taiwan)
15:55 - 16:00	P4 S078 Lumbar Stiffness After Pan-Lumbar Arthrodesis Adversely Affects Patient-Reported Outcomes but Does Not Compromise Patient Satisfaction in Adult Spinal Deformity	Se-Jun Park (Korea)

Scientific Program

P : Podium No.

May 22 (Thu)		Crystal Ballroom B (2F)
16:00 - 16:10	Discussion	
16:10 - 16:40	KSSS Research Award (Crystal Ballroom A)	
16:40 - 17:10	KSSS General Assembly (Crystal Ballroom A)	
17:10 - 17:20	Group Photo (Crystal Ballroom A)	
17:20 - 18:20	Cocktail Reception (Exhibition Hall, 2F)	
18:20 - 20:20	Gala Dinner (Crystal Ballroom A+B)	

Scientific Program

P : Podium No.

May 23 (Fri)		Crystal Ballroom A (2F)	
07:20 - 07:50	Breakfast Symposium III		Dong-Gune Chang (Korea)
07:20 - 07:35	P1	[Sponsored by Medyssey]  CeLaPla® Plate Fixation System in Cervical Open-Door Laminoplasty: Early Clinical Insights	Byung-Taek Kwon (Korea)
07:35 - 07:50	P1	[Sponsored by Myungmoon Pharm Co., Ltd]  Myungmoon Pharm. Co., Ltd. The Clinical Benefits of Muscle Relaxants and NSAIDs Combination Therapy in Low Back Pain	Seong-Hun Choi (Korea)
08:00 - 08:30	Best Paper Candidates Presentation I (Domestic)		Jungsub Lee (Korea) Eun-Min Seo (Korea)
08:00 - 08:05	P1	S079 Impact of Restricted Prophylactic Antibiotic Guideline on Surgical Site Infection Rates Following Spinal Surgery: A Nationwide Cohort Analysis	Hyung-Youl Park (Korea)
08:05 - 08:10	P2	S080 Deep Learning-Based Object Detection Algorithm Using Magnetic Resonance Imaging for Differential Diagnosis of Pathological Vertebral Fractures Caused by Malignant Metastasis in Patients with Vertebral Compression Fractures: A Retrospective Multicenter St	Joonghyun Ahn (Korea)
08:10 - 08:15	P1	S081 Sacral Insufficiency Fractures in Postmenopausal Women with Low Back and Buttock Pain: Prevalence and Risk Factor Analysis in 752 Patients	Hyun-Jun Kim (Korea)
08:15 - 08:20	P2	S082 Role of Mitofusion 1 in Mitochondrial Quality Control and the Anti-Inflammatory Effects in Nucleus Pulposus Cells During Inflammation-Induced Degeneration	Jaewon Shin (Korea)
08:20 - 08:30	Discussion		
08:30 - 09:00	Best Paper Candidates Presentation II (Domestic)		Dong Ki Ahn (Korea) Ho-Jin Lee (Korea)
08:30 - 08:35	P1	S083 Real-Time Locating System (RTLS) Analysis of Early Postoperative Recovery: A Comparison Between Biportal Endoscopic Spine Surgery (BEES) and Traditional Open Surgery	Sub-Ri Park (Korea)
08:35 - 08:40	P2	S084 Cervical Nerve Root Variations: Observations During Full-Endoscopic Spine Surgery	Myeongguk Jo (Korea)
08:40 - 08:45	P1	S085 In Vitro Comparison of Endplate Preparation in Biportal Endoscopic and Microscopic Tubular Transforaminal Lumbar Interbody Fusion Procedures	Hyun-Jin Park (Korea)

Scientific Program

P : Podium No.

May 23 (Fri)		Crystal Ballroom A (2F)
08:45 - 08:50	P2 S086 The Natural History of Duchenne Muscular Dystrophy Scoliosis in Corticosteroid Era: A Mean 15-Year Follow-Up Study	Sung Taeck Kim (Korea)
08:50 - 09:00	Discussion	
09:00 - 09:30	Best Paper Candidates Presentation III (Domestic)	Young Woo Kim (Korea) Sung-Woo Choi (Korea)
09:00 - 09:05	P1 S087 Effectiveness in the Referral of Adolescent Idiopathic Scoliosis by Health-Care Professionals: A Single-Center Retrospective Study for Assessing the Role of School-Based Scoliosis Screening in South Korea	Dong Yun Kim (Korea)
09:05 - 09:10	P2 S088 Relationship Between Improvement in Functional Mobility Tests and Spinopelvic Parameters, Patient-Reported Outcomes Following Adult Spine Deformity Surgery	Bong-Su MUN (Korea)
09:10 - 09:15	P1 S089 Radiographic Progression of Lumbar Degenerative Spondylolisthesis: Natural History and Associated Risk Factors	Hae-Dong Jang (Korea)
09:15 - 09:20	P2 S090 Analysis of Risk Factors for Vertebral Body Subsidence After Oblique lumbar Interbody Fusion: Extraction of Region of Interest Values for Vertebral Endplate Compartmentalization	Sang Ho Kim (Korea)
09:20 - 09:30	Discussion	
09:30 - 10:00	Best Paper Candidates Presentation IV (International)	Soo Taek Lim (Korea) Jae Hyuk Yang (Korea)
09:30 - 09:35	P1 S091 Circumferential Bioelectronics Enable Spinal Cord Recording and Stimulation Bypass Following Spinal Cord Injury	Jiang Lei (Singapore)
09:35 - 09:40	P2 S092 Tapping the Role of Wnt Signaling for Neural Regeneration in Spinal Cord Injury - A Novel Approach	Sudhir Ganesan (India)
09:40 - 09:45	P1 S093 International External Validation of the SORG Machine Learning Algorithm for Predicting Sustained Postoperative Opioid Prescription After Anterior Cervical Discectomy and Fusion Using a Taiwanese Cohort of 1,037 Patients	Jui-Yo Hsu (Taiwan)
09:45 - 09:50	P2 S094 Short Segment Posterior Fixation Including the Fracture Level Purveys Good Outcomes in Unstable Thoracolumbar Burst Fractures	Vaskar Humagain (Nepal)
09:50 - 10:00	Discussion	
10:00 - 10:20	Coffee Break	

Scientific Program

P : Podium No.

May 23 (Fri)		Crystal Ballroom A (2F)
10:20 - 11:10	Plenary Lecture II	Jong-Beom Park (Korea)
10:20 - 10:40	P1 S095 Transdiscal Osteotomy, Anterior Column Realignment, and Other Alternatives to the Pedicle Subtraction Osteotomies Technique	Sangwook Tim Yoon (USA)
10:40 - 11:00	P1 S096 Artificial Intelligence in Spine Surgery	Sangwook Tim Yoon (USA)
11:00 - 11:10	Discussion	
11:10 - 11:30	Invited Lecture V	Kyung-Soo Suk (Korea)
11:10 - 11:25	P1 S097 Lessons Learned from Cervical Disc Arthroplasty	Kee D. Kim (USA)
11:25 - 11:30	Discussion	
11:30 - 12:00	Best Paper Candidates Presentation V (International)	Hong Moon Sohn (Korea) Sang-Bum Kim (Korea)
11:30 - 11:35	P1 S098 Evaluation of Osteoporosis and Sarcopenia on Outcomes of Fusion in MIS-TLIF	Tay Hui Wen (Singapore)
11:35 - 11:40	P2 S099 Intraoperative Neuromonitoring Use in Posterior Endoscopic Cervical Decompression: Can It Reduce Complications?	Peem Sarasombath (Thailand)
11:40 - 11:45	P1 S100 Outcome of Posterior Short Segment Fixation With and Without Index Screws in Thoracolumbar Burst Fractures	Nyan Lin Aung (Myanmar)
11:45 - 11:50	P2 S101 Is C2 Translaminar Screw Feasible in Nepalese Population? A Morphometric Study of C2 Lamina Using Computed Tomography in Nepalese Adults	Pratap Babu Bhandari (Nepal)
11:50 - 12:00	Discussion	
12:00 - 12:30	Best Paper Candidates Presentation VI (International)	Seung Deok Sun (Korea), Young Bae Kim (Korea)
12:00 - 12:05	P1 S102 Augmented Reality in Spine Surgery	Xian Jun Ngoh (Singapore)
12:05 - 12:10	P2 S103 Efficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF: Double Blinded, Randomized Control Trial	Konthorn Chankong (Thailand)
12:10 - 12:15	P1 S104 Beyond the Operating Room: The Impact of Biopsychosocial Factors on Lumbar Surgery Outcomes	Rupinder Pal Singh Chahal (India)
12:15 - 12:20	P2 S105 Prevalence and Impact of Incidental Thoracic Spinal Stenosis in Patients undergoing Lumbar Fusion Surgery	Jeremy Tze En Lim (Singapore)

Scientific Program

P : Podium No.

May 23 (Fri)		Crystal Ballroom A (2F)
12:20 - 12:30	Discussion	
12:30 - 13:30	Luncheon Symposium III	Kyung-Soo Suk (Korea)
12:30 - 13:00	P1 [Sponsored by CGBIO]  rhBMP-2: How to Improve the Fusion Without Complication	Hee Jung Son (Korea)
13:00 - 13:30	P1 [Sponsored by Hanmi Pharmaceutical]  Hanmi Pharm. Efficacy & Safety from a Global Phase 3 Trial Including Korean: Obodence (Denosumab Biosimilar)	Jiwon Kwon (Korea)
13:30 - 14:30	Symposium (III) Lumbar: Lumbo-Pelvic-Hip Complex	Youngdo Koh (Korea) Hun Kyu Shin (Korea)
13:30 - 13:42	P1 S106 Anatomical Characteristics and Functional Significance of the Pelvis	Ki-Han You (Korea)
13:42 - 13:54	P2 S107 Alignment and Biomechanical Relationships Among the Lumbar Spine, Pelvis, and Hip Joint	Jae Hwan Cho (Korea)
13:54 - 14:06	P1 S108 The Impact of Pelvic Imbalance on Lumbar Spine and Lower Limb	Tae-Hoon Kim (Korea)
14:06 - 14:18	P2 S109 The Effects of Lower Limb Imbalance on Lumbar Spine	Yong Chan Kim (Korea)
14:18 - 14:30	Discussion	
14:30 - 14:50	Invited Lecture VII	Jin Hwan Kim (Korea)
14:30 - 14:45	P1 S110 Solid Rod Tether for Thoracic Scoliosis? An Analysis of Progressive Curve Straightening Behaviour in Anterior Thoracic Spinal Fusion	Hee-Kit Wong (Singapore)
14:45 - 14:50	Discussion	
14:50 - 15:10	Coffee Break	
15:10 - 15:40	Deformity (5)	Nam-Su Chung (Korea) Jae Hyuk Yang (Korea)
15:10 - 15:15	P1 S111 Evaluating the Efficacy and Safety of Halo-Femoral Traction and Halo-Gravity Traction Techniques in Severe Kyphoscoliosis with Spinal Cord Risk Classification (SCRC) Type 3 over the Apex	Yuan-Shun Lo (Taiwan)
15:15 - 15:20	P2 S112 Curve Regression in Mild Adolescent Idiopathic Scoliosis Treated with Periodic Padding Adjustment with Rigo-Cheneau Orthosis	Ronald P. Tangente (Philippines)

Scientific Program

P : Podium No.

May 23 (Fri)		Crystal Ballroom A (2F)	
15:20 - 15:25	P1	S113 Role of Preoperative Halo-Gravity Traction in Management of Pediatric Severe Spinal Deformities	Tarun Suri (<i>India</i>)
15:25 - 15:30	P2	S114 Risk Factor of Scoliosis After Hip Reconstructive Surgery in Patients with Spastic Quadriplegic Cerebral Palsy	Kun Bo Park (<i>Korea</i>)
15:30 - 15:40		Discussion	
15:40 - 16:10		Infection	Hwa-Yeop Na (<i>Korea</i>) Sung-Kyun Oh (<i>Korea</i>)
15:40 - 15:45	P1	S115 The Paradigm Shift: Emergence of MDR Gram Negative Bacteria in Post Operative Spinal Infections: Causes, Prevention and Management	Raghava D Mulukutla (<i>India</i>)
15:45 - 15:50	P2	S116 Surgical Management of Paediatric Spinal Tuberculosis: A 9-Year Experience	Deepak Kaucha (<i>Nepal</i>)
15:50 - 15:55	P1	S117 A Descriptive Study on the Clinical Profile, Management, and Outcomes of Pediatric Patients with Pott's Disease at the Philippine General Hospital	Anne Kathleen Batto Ganai-Antonio (<i>Philippines</i>)
15:55 - 16:00	P2	S118 Dual Infection in Spine - Tubercular and Pyogenic: An Extremely Rare Case Report	Shahidul Islam (<i>Bangladesh</i>)
16:00 - 16:10		Discussion	
16:10 - 16:50		Asian Spine Society Traveling Fellowship & Visiting Reports (Crystal Ballroom A)	
		Traveling Fellowship Reports	
16:10 - 16:22	P1	Japan	Dong-Ho Kang (<i>Korea</i>)
16:22 - 16:34	P1	Taiwan	Sung Tan Cho (<i>Korea</i>)
		Visiting Reports	
16:34 - 16:42	P1	India	Ho-Jin Lee (<i>Korea</i>)
16:42 - 16:50	P1	Thailand	Sang-Bum Kim (<i>Korea</i>)
16:50 - 17:10		Best Paper Awards (Crystal Ballroom A)	
17:10 - 17:20		Closing Remarks (Crystal Ballroom A)	
17:20 - 17:30		Farewell and Inauguration Ceremony for the President of KSSS (Crystal Ballroom A)	

Scientific Program

P : Podium No.

May 23 (Fri)		Crystal Ballroom B (2F)
07:20 - 07:50	Breakfast Symposium IV	Byung-Ho Lee (Korea)
07:20 - 07:35	P3 [Sponsored by SK Chemicals]  The Anabolic Agent for Osteoporosis, Teriparatide	Wooseok Jung (Korea)
07:35 - 07:50	P3 [Sponsored by Baxter]  Right Product for Right Clinical Outcome in Spine Surgery	Namhoo Kim (Korea)
08:00 - 08:30	Lumbar (4)	Seong Jun Ahn (Korea) Dae-Hyun Park (Korea)
08:00 - 08:05	P3 S119 Accuracy of Postero-Superior Iliac Spine Reference Array Placement in Robot-Navigated Spine Surgery	Joseph Wan (Singapore)
08:05 - 08:10	P4 S120 Awake Endoscopic Lumbar Spinal Decompression on a Patient with Achondroplasia - Literature Review and Case Report	Jeremy Tan (Singapore)
08:10 - 08:15	P3 S121 Lumbar Spinal Stenosis: An Update on the Epidemiology, Diagnosis and Operative Complication	Tajuddin Molla (Bangladesh)
08:15 - 08:20	P4 S122 Anterior to Psoas Lateral Lumbar Interbody Fusion vs Transforaminal Lumbar Interbody Fusion: Early Clinical and Radiologic Outcomes	Jose Joefrey Fontanilla Arbatin (Philippines)
08:20 - 08:30	Discussion	
08:30 - 09:00	MIS (1)	Hyoung-Yeon Seo (Korea) Jae-Young Hong (Korea)
08:30 - 08:35	P3 S123 A Single Surgeon's Experience Transitioning from Tubular-Based Microscopic Decompression to Full-Endoscopic Decompression for Lumbar Spinal Stenosis	Marcus W Tan (Singapore)
08:35 - 08:40	P4 S124 Clinical Efficacy of Biportal Endoscopic Spinal Surgery (BESS) for Lumbar Spinal Stenosis	Sung-nyun Baek (Korea)
08:40 - 08:45	P3 S125 Can Cauda Equina Syndrome Caused by Lumbar Herniated Intervertebral Disc Be Treated with Biportal Endoscopic Technique? A Retrospective Cohort Study	Sang-Min Park (Korea)
08:45 - 08:50	P4 S126 Are Surgeries for Lumbar Facet Cysts a Thing of the Past? Evaluating Efficacy of Percutaneous Facet Cyst Rupture as a Primary Treatment Modality	Priyank Patel (India)
08:50 - 09:00	Discussion	

Scientific Program

P : Podium No.

May 23 (Fri)		Crystal Ballroom B (2F)
09:00 - 09:30	MIS (2)	Yung Park (Korea) Si-Young Park (Korea)
09:00 - 09:05	P3 S127 Distance to the Spinal Canal and Vertebral Body from the Insertion Point of Percutaneous Pedicle Screws in the Lumbar Spine: Radiographic Anatomy on Computed Tomography Images for a Safe and Efficient Procedure	Takeshi Aoyama (Japan)
09:05 - 09:10	P4 S128 Clinical and Radiological Comparison of Biportal Endoscopic Interbody Fusion and DLIF-ALIF	Seung Deok Sun (Korea)
09:10 - 09:15	P3 S129 Application of BE-TLIF in Lytic and Degenerative Spondylolistheses-Cases Series	Che Wei Liu (Taiwan)
09:15 - 09:20	P4 S130 In Vivo Comparison of Endplate Preparation Quality Between Biportal Endoscopic and Conventional Transforaminal Lumbar Interbody Fusion: An Endoscopic Assessment	Sang-Min Park (Korea)
09:20 - 09:30	Discussion	
09:30 - 10:00	MIS (3)	Kee-Won Rhyu (Korea) Kwang-Sup Song (Korea)
09:30 - 09:35	P3 S131 Functional Outcome of Modified Oblique Lateral Interbody Fusion Approach for Degenerative Lumbar Spine Pathology	Aditya Thakur (India)
09:35 - 09:40	P4 S132 The Adequate Range of Facet Resection in Full Endoscopic PECF (Percutaneous Endoscopic Cervical Foraminotomy)	JaeHung Shin (Korea)
09:40 - 09:45	P3 S133 XLIF: The Filipino Experience	Roy Michael Gonzaga Domacena (Philippines)
09:45 - 09:50	P4 S134 Educational Value of a High-Definition Three-Dimensional Extracorporeal Telescope (Exoscope) in Lateral Access Spine Surgery	Terry Hong Lee Teo (Singapore)
09:50 - 10:00	Discussion	
10:00 - 10:20	Coffee Break	
10:20 - 11:10	Plenary Lecture II (Crystal Ballroom A)	Jong-Beom Park (Korea)
11:10 - 11:30	Invited Lecture VI	Woo-Dong Nam (Korea)
11:10 - 11:25	P3 S135 The Application of Computerized Navigation and 3D Printed Model in Complex Paediatric Spinal Deformity	Chun-Man Ma (Hong Kong)
11:25 - 11:30	Discussion	

Scientific Program

P : Podium No.

May 23 (Fri)		Crystal Ballroom B (2F)
11:30 - 12:00	MIS (4)	Chung-Hwan Kim (Korea) Se-Jun Park (Korea)
11:30 - 11:35	P3 S136 UBE ExLLIF with Large Cage by UBEST Technique - Results from Our Early Experience	Sudhir Ganesan (India)
11:35 - 11:40	P4 S137 Biportal Endoscopic Lumbosacral Inclinator Extraoraminial Approach for Delayed L5 Root Palsy After Malunion of Vertically Unstable Sacral Alar Fracture	Min Seok Kang (Korea)
11:40 - 11:45	P3 S138 Exploring the Efficacy of Minimally Invasive Spine Fixation in Thoracolumbar Spinal Injuries	Md. Ziaul Hasan (Bangladesh)
11:45 - 11:50	P4 S139 Lateral Lumbar Interbody Fusion with a Bone Defect in Vertebral Body: Autobone Overlapping Technique	Chungwon Bang (Korea)
11:50 - 12:00	Discussion	
12:00 - 12:30	Tumor	Chang-Bae Kong (Korea) Jae Hwan Cho (Korea)
12:00 - 12:05	P3 S140 Which Scoring System Best Predicts Long-Term Survival in Patients with Spinal Metastasis in the Era of Targeted Systemic Treatment?	Dong-Ho Kang (Korea)
12:05 - 12:10	P4 S141 Treatment Approach for Bilsky Grade 2 Metastatic Epidural Spinal Cord Compression Based on Radiation Therapy Failure Risk	Sehan Park (Korea)
12:10 - 12:15	P3 S142 Machine Learning Versus Logistic Regression: Predicting One-Year Survival in Patients with Spinal Metastasis Undergoing Surgery	Dong-Ho Kang (Korea)
12:15 - 12:20	P4 S143 Realtime Vertebral Artery Visualization Using Microscope-Based Augmented Reality Navigation in Cervical Dumbbell-Type Spinal Cord Tumor Resection	Fumitake Tezuka (Japan)
12:20 - 12:30	Discussion	
12:30 - 13:30	Luncheon Symposium IV	Jin Sup Yeom (Korea)
12:30 - 13:00	[Sponsored by Amgen & Chong Kun Dang] AMGEN x  P3 Building Stronger Bones: The Role of EVENITY and Prolia in Osteoporosis Management	Sam Yeol Chang (Korea)
13:00 - 13:30	[Sponsored by Daiichi Sankyo]  P3 Beyond Conventional: Mirogabalin for Neuropathic Pain	Sang-Min Park (Korea)

Scientific Program

P : Podium No.

May 23 (Fri)		Crystal Ballroom B (2F)
13:30 - 14:30	Symposium (IV) MIS: Practice-Based	
13:30 - 14:00	Session 1: Present and Future of Endoscopic Spinal Surgery	Seok Woo Kim (Korea) Deuk Soo Jun (Korea)
13:30 - 13:38	P3 S144 Current Status of Spinal Endoscopy in Korea	Hyun-Jin Park (Korea)
13:38 - 13:46	P4 S145 Application of Navigation with Endoscopy	Min-Seok Kang (Korea)
13:46 - 13:54	P3 S146 Application of Robot with Endoscopy	Sang-Min Park (Korea)
13:54 - 14:00	Discussion	
14:00 - 14:30	Session 2: Advance MIS-Spine Surgery	Chang-Nam Kang (Korea) Jae Chul Lee (Korea)
14:00 - 14:08	P3 S147 Biportal Endoscopic Cervical Laminectomy for Cervical Myelopathy	Ju Eun Kim (Korea)
14:08 - 14:16	P4 S148 Full Endoscope Assisted Lumbar Interbody Fusion	JaeHung Shin (Korea)
14:16 - 14:24	P3 S149 LLIF	Hee Jung Son (Korea)
14:24 - 14:30	Discussion	
14:30 - 14:50	Invited Lecture VIII	Seok Woo Kim (Korea)
14:30 - 14:45	P3 S150 Cervical Deformity Surgery: A Thoughtful Approach to Level Selection	Thanut Valleenukul (Thailand)
14:45 - 14:50	Discussion	
14:50 - 15:10	Coffee Break	
15:10 - 15:40	Trauma	Jin Hwan Kim (Korea) Byung-Ho Lee (Korea)
15:10 - 15:15	P3 S151 Initial Clinical Experience with Spine Jack in Thoracolumbar Vertebral Compression Fractures: A Comparative Analysis with Kyphoplasty	SooHyun Oh (Korea)
15:15 - 15:20	P4 S152 Comparative Outcomes of Autologous Iliac Bone Strut Graft vs. Titanium Mesh Cage in Anterior Corpectomy for Thoracolumbar Burst Fractures	Hee-Woong Chung (Korea)
15:20 - 15:25	P3 S153 Atypical H-Sacral Fracture with Bilateral Gluteal Morel Lavallee: Case Report and Literature Review	Satpal Singh Charl A/L Gurmit Singh (Malaysia)

Scientific Program

P : Podium No.

May 23 (Fri)		Crystal Ballroom B (2F)
15:25 - 15:30	P4 S154 Compression Rate Progression of Osteoporotic Vertebral Compression Fracture in Conservative Treatment	Jaewan Soh (Korea)
15:30 - 15:40	Discussion	
15:40 - 16:10	Miscellaneous	Seong Jun Ahn (Korea), EunSeok Son (Korea)
15:40 - 15:45	P3 S155 Defining Optimal Post-Void Residual Volume Thresholds for Predicting Delayed Postoperative Urinary Retention in Spinal Surgery	Jaenam Lee (Korea)
15:45 - 15:50	P4 S156 Impact of Smoking, Diabetes, and Exercise on Dementia Risk in Women with Osteoporosis: A Nationwide Cohort Study	Hee Jung Son (Korea)
15:50 - 15:55	P3 S157 Vanadium Allergy in Spine Surgery: An Emerging Concern in Metal Hypersensitivity	Eugene Tze Chun Lau (Singapore)
15:55 - 16:00	P4 S158 Comparative Analysis of Clinical and Radiographic Outcomes Between Posterior and Posterolateral Extraforaminal Epidural Injections in Cervical Radiculopathy Patients	Sung Hoon Choi (Korea)
16:00 - 16:10	Discussion	
16:10 - 16:50	Asian Spine Society Traveling Fellowship & Visiting Reports (Crystal Ballroom A)	
16:50 - 17:10	Best Paper Awards (Crystal Ballroom A)	
17:10 - 17:20	Closing Remarks (Crystal Ballroom A)	
17:20 - 17:30	Farewell and Inauguration Ceremony for the President of KSSS (Crystal Ballroom A)	

e-Poster Session

The e-Posters will be displayed electronically on laptops provided at the venue. These laptops will be available for continuous viewing throughout the event, allowing attendees to browse the e-Posters at their convenience.

• 08:00-17:00, May 22 (Thu) - 23 (Fri), 2025

• Emerald Room Foyer (2F)

Poster Code	Abstract No.	Abstract Title	Name
E001	2025S-003	Clinical Significance, Challenges, and Management Strategies of Incidental Extrapinal Findings in Cervical Spine MRI: A Retrospective Analysis of 2,286 Cases	Seung Myung Wi (<i>Korea</i>)
E002	2025S-009	Endoscopic Decompression for Radiculopathy in Scoliosis	Jun Rui Don Koh (<i>Singapore</i>)
E003	2025S-016	Functional Outcome of Percutaneous Transforaminal Endoscopic Lumbar Discectomy in PIVD: Our Early Report	Tej Prakash Dawadi (<i>Nepal</i>)
E004	2025S-021	The Effect of Surgical Correction of Adolescent Idiopathic Scoliosis on Pelvic Obliquity	Avinash KC (<i>Nepal</i>)
E005	2025S-022	Outcomes of Transforaminal Epidural Steroid Injection in Patients with Lower Limb Radiculopathy	Lwin Bo Bo Soe (<i>Myanmar</i>)
E006	2025S-023	Cauda Equina Syndrome Treated with Two Level Endoscopic Discectomy	Navindran Nair (<i>Malaysia</i>)
E007	2025S-027	Clinical Outcome Study of Primary Intra-Spinal Tumour at Yangon Orthopaedic Hospital	Win Myint Han (<i>Myanmar</i>)
E008	2025S-057	Actinomyces Thoracic Spondylitis: A Rare Occurrence in Spine Infection	Heng Keat Tan (<i>Malaysia</i>)
E009	2025S-069	Full Endoscopic En Bloc Flavectomy Technique for Lumbar Spinal Stenosis: A Technical Note	Gian Karlo Ponce Dadufalza (<i>Philippines</i>)
E010	2025S-089	Unraveling Spinopelvic Dissociation: Insights from 7 Cases Treated in a Year at Malacca General Hospital	Muhamad Zharif Nor Asikin (<i>Malaysia</i>)
E011	2025S-091	Functional Outcome of Minimally Invasive Anterior Surgery for Anterior Spinal Disease	Aditya Thakur (<i>India</i>)
E012	2025S-101	Navigation in Cervical Spine Surgery	Chien-chun Chang (<i>Taiwan</i>)

Poster Code	Abstract No.	Abstract Title	Name
E013	2025S-107	Effectiveness of PICO Dressing in Managing Spinal Wound Complications	Chin-Pei Bong <i>(Malaysia)</i>
E014	2025S-111	Is Anterior Cervical Discectomy and Fusion (ACDF) a Reasonable First Choice for Giant Cervical Disc Herniation?	Hyo Sae Ahn <i>(Korea)</i>
E015	2025S-119	Epidural PRP Injection: An Alternative Treatment of Spinal Pain	Shahidul Islam <i>(Bangladesh)</i>
E016	2025S-130	Functional Outcome of ACDF with Stand Alone Cage and Bone Graft in Degenerative Cervical Disc Prolapse with Neurological Deficits	Md. Asraf UI Matin <i>(Bangladesh)</i>
E017	2025S-134	Biportal Endoscopic Transforaminal Lumbar Interbody Fusion Using Double Cages for Degenerative Spondylolisthesis Grade 2 with Calcified Disc	Prahesta Adi Wibowo <i>(Indonesia)</i>
E018	2025S-135	The Effect of Preoperative Embolization on Intraoperative Bleeding in Posterior Stabilization of Thoracolumbar Spine Fractures	Tommy Suharso <i>(Indonesia)</i>
E019	2025S-136	Contralateral Foraminal Area Increases Significantly After Minimally Invasive Transforaminal Lumbar Interbody Fusion Using Biplanar Expandable Cage	Yee Gen Lim <i>(Singapore)</i>
E020	2025S-138	Efficacy, Safety, and Reliability of the Single Anterior Approach for Subaxial Cervical Spine Dislocation	Erfanul Huq Siddiqui <i>(Bangladesh)</i>

Video Session

Video session offers a more visual way to learn new and innovative techniques in spine surgery. All participants are invited to join 10 video presentations throughout the conference.

The videos will be played on a large LED screen in the Emerald Room. Alternatively, you may choose and watch any video at your convenience using laptops in the e-Poster Session, located in the Emerald Room Foyer.


• 08:00-17:00, May 22 (Thu) - 23 (Fri), 2025

• Emerald Room & Foyer (2F)

Topic	Title	Name
Cervical	En Bloc Extensive Dome-Like Laminoplasty for Severe C2-3 Cord Compression	Kyung-Chung Kang (Korea)
	Full-Endoscopic Cervical Foraminal Decompression - How to Do? -	Taeksoo Jeon (Korea)
Lumbar	Oblique Lumbar Interbody Fusion: Essential Technical Tips and Surgical Considerations	Byung-Ho Lee (Korea)
	Endoscopic Decompression of L5 Far-out Syndrome	In Seok Son (Korea)
MIS	Endoscopic Lumbar Fusion	Sang-Min Park (Korea)
	Navigation-Based Spine Surgery	Jiwon Kwon (Korea)
Deformity	Posterior Vertebral Column Resection	Se-Jun Park (Korea)
	Pedicle Subtraction Osteotomy	Hojoong Kim (Korea)
Tumor	Lamina Recapping Technique in Spinal Cord Tumor	Yunjin Nam (Korea)
	Anterior Vertebral Column Resection in Chondrosarcoma	Jae Hwan Cho (Korea)

Venue Information

36F



Belle-Vue Suite

- Basic Research Symposium (May 21)
- Welcome Reception (May 21)


Astor Suite

- Presidential Roundtable Meeting (May 21)

Charlotte

- Cocktail Reception (May 21)

2F



Crystal Ballroom

- Opening Remarks (May 22)
- Plenary & Parallel Sessions (May 22-23)
- KSSS Research Award (May 22)
- KSSS General Assembly (May 22)
- Gala Dinner (May 22)
- Best Paper Awards (May 23)
- Farewell & Inauguration Ceremony (May 23)

Emerald Room

- Video Session (May 22-23)
- Exhibition (May 22-23)

Emerald Room Foyer

- Preview Room (May 22-23) ★
- Video & e-Poster Session (May 22-23) ★


Jade Room

- VIP Room (May 22-23)

2F Foyer

- Exhibition (May 22-23)
- Registration Desk (May 22-23)

Booth Layout



Booth No.	COMPANY	Booth No.	COMPANY	Booth No.	COMPANY
1, 2, 3, 4	GS Medical	70, 29	SK Chemicals	50	Samjin Pharm.
5, 68	Medtronic Korea	30	BMI Korea	51	ALPHANOX
6, 18	VIATRIS KOREA	31, 32, 33, 34	Daiichi Sankyo Korea	52	ALTEOGEN Inc.
7, 8, 9, 10	Daewon Pharmaceutical Co., Ltd	35	Stryker Korea	53	HansBiomed
11, 12, 13, 14	CGBIO Co., Ltd.	36	Corentec	54	Sometech Inc.
15, 16, 69, 17	DAEWOONG PHARMACEUTICAL	37	Shin Poong Pharm., Co. Ltd.	55	Osteonic
19, 20, 21, 22	DONG-A ST	38	Seolim	56	DRTECH
23	DUT Korea	39, 40	Baxter Korea	57, 58	Dalim Medical
24	LG Chem Ltd.	41, 42	HK inno.N	59, 60	Medyssey
25	Yungjin Pharm. Co., Ltd	43, 44, 45, 71	Amgen & Chong Kun Dang	61	Mantiz
26	ZEISS Korea	46	GE Health Care Korea	62	Chodang Pharm
27, 28	MYUNGMOON Pharm co.,Ltd	47	Philips Korea	63, 64, 65, 66	Hanmi Pharmaceutical
		48	SpinoTech	67	Genoss Co., Ltd.
		49	Ilyang Pharm		

Coffee Booth

Conference Information

Registration

All participants are required to wear their badges throughout the Conference. Failure to do so may result in limited access to sessions, exhibitions, and other activities.

Operating Hours and Locations:

- 36F Belle-Vue Suite Foyer, 13:00 – 18:00, May 21 (Wed), 2025
- 2F Foyer, 06:30 - 18:00, May 22 (Thu) / 06:30 - 17:30, May 23 (Fri), 2025

Registration Fee Includes:

- Admission to all sessions & exhibition
- Access to the Welcome Reception and Gala Dinner
- Daily breakfast, lunch, and coffee breaks
- Congress kit, including the program book

On-site Registration Fee

On-site registration will be available during the congress with the following registration fees. Please note that on-site registration only accepts credit card payments (VISA, Master, JCB, and AMEX are accepted).

Category	Fee
KSSS Member MD	USD 160 (KRW 200,000)
KSSS Non-Member MD	USD 180 (KRW 220,000)
Residents or Equivalents*	USD 120 (KRW 140,000)

* Equivalents: Army doctors, nurses, researchers and medical students

Video & e-Poster Session

The e-Posters will be displayed electronically on laptops. Please note that e-Poster presenters do not have designated presentation times.

The videos will be played on a large LED screen in the Emerald Room. Alternatively, you may browse and watch any video at your convenience using laptops in the Video & e-Poster session.

Video & e-Poster Session

- 08:00 - 17:00, May 22 (Thu) - 23 (Fri), 2025
- Emerald Room Foyer (2F)

Video Session

- 08:00 - 17:00, May 22 (Thu) - 23 (Fri), 2025
- Emerald Room & Foyer (2F)

Preview Room

All speakers (excluding e-Poster and Video presenters) must check in at the Preview Room at least 2 hours before their session. If your presentation is scheduled in the morning on May 22, please make sure to visit the preview room at 6:30 AM to avoid any delays. **Presentation files can be checked and edited on-site, which is especially important if they contain any video or audio files.**

- 06:30 - 17:00, May 22 (Thu) - 23 (Fri), 2025

- Emerald Room Foyer

Breakfast

A semi-buffet will be provided for the Breakfast Symposium, sponsored by our Gold sponsors.

- 06:40 - 07:40, May 22 (Thu), 2025

- 06:50 - 07:50, May 23 (Fri), 2025

- Crystal Ballroom A & B

Lunch

Lunch boxes, sponsored by our Platinum sponsors, will be provided during the Luncheon Symposium.

- 12:00 - 13:00, May 22 (Thu), 2025

- 12:30 - 13:30, May 23 (Fri), 2025

- Crystal Ballroom A & B

Souvenir: Create Your Own Luggage Tag

We're offering hand-printed, custom leather luggage tags to the first 150 participants — available on a first-come, first-served basis. Each tag is personalized with engraved initials, making it a unique keepsake from the event.

- 09:00 - 16:00, May 22 (Thu) - 23 (Fri), 2025

- Athene Garden (3F)

Social Programs

Welcome Reception

Connect with fellow participants and enjoy a delightful evening of networking, food, and drinks. A great opportunity to build professional relationships and friendships.

- 18:10 - 20:10, May 21 (Wed), 2025
- Belle-Vue Suite, 36F
- Cocktail Reception: 17:10 - 18:10 at Charlotte Suite, 36F

KSSS Research Award

- 16:10 - 16:40, May 22 (Thu), 2025
- Crystal Ballroom A, 2F

KSSS General Assembly

All members of the Korean Society of Spine Surgery are cordially invited to attend the general assembly, which will be conducted in Korean.

- 16:40-17:10, May 22 (Thu), 2025
- Crystal Ballroom A, 2F

Gala Dinner

Celebrate with us at the Gala Dinner in the elegant Crystal Ballroom. After the cocktail reception, enjoy a memorable evening of fine dining and great company.

- 18:20 - 20:20, May 22 (Thu), 2025
- Crystal Ballroom A & B, 2F
- Cocktail Reception: 17:20-18:20 at the Exhibition Hall, 2F

Best Paper Awards

- 16:50 - 17:10, May 23 (Fri), 2025
- Crystal Ballroom A, 2F

Farewell and Inauguration Ceremony for the President of KSSS

- 17:20-17:30, May 23 (Fri), 2025
- Crystal Ballroom A, 2F

Stamp Tour Event

We invite all participants to become explorers and visit all the exhibitors. Visit every exhibition booth, collect stamps, and enter our exciting lucky draw!

How to Join the Stamp Tour Event

- STEP 1** Use the Stamp Tour Card included in your Congress Kit to collect stamps by visiting exhibition booths in sections A to C of the Exhibition Hall.
- STEP 2** Cards and stamp colors differ by date, so please make sure to collect the correct stamps on the corresponding day's card.
- STEP 3** Submit your completed card at the registration desk.
- STEP 4** Be sure to attend the Lucky Draw for a chance to win! Only on-site participants will be eligible to claim prizes.

Lucky Draw #1 at the Gala Dinner

- 18:20 - 20:20, May 22 (Thu), 2025
- Crystal Ballroom A & B

Lucky Draw #2 at the Best Paper Awards

- 16:50 - 17:10, May 23 (Fri), 2025
- Crystal Ballroom A



Great Places to Visit within Walking Distance of Lotte Hotel



Deoksugung Palace

Deoksugung Palace is one of five royal palace Remained in Seoul. Mainly built during the near the tum of the 20th century, Deoksugung is the smallest of Seoul's palaces. The name Deoksugung means "palace of virture and signifies longevity" in the spirit of praying for long life for Emperor Gojong. Located at the corner of Seoul's busiest downtown intersection, Deoksugung palace is famous for its elegant stone-wall road.



Myeong-dong

Myeongdong is Seoul's shopping districts and is a must-see for tourists, but it is not just a shopping destination; Myeongdong is also a hub of commerce, banking and culture with a daytime population of 1.5-2 million. For shoppers there is a mixture of street stalls and retail outlets selling everything from high fashion to casual attire, as well as many Korean cosmetics stores offering high-quality products at competitive prices.



Gyeongbokgung Palace

Gyeongbokgung Palace is the prime palace of the Joseon Dynasty that was built in 1395 (the 4th year of King Taejo's reign) to move the capital to Hanyang after the founding of the Joseon Dynasty in 1392. It was the center of Hanyang built against the backdrop of Baegaksan Mountain (now Bugaksan Mountain) in the north and with a wide Yukjogeor Street (now Sejong-ro) in front of the main entrance, Gwanghwamun Gate.



Insa-dong

Insa-dong, located in the heart of the city, is an important place where old but precious traditional goods are on display. There is one main road in Insa-dong with alleys on each side. Within these alleys are galleries, traditional restaurants, teahouses, and cafes. The galleries are the heartbeat of Insa-dong. There are about 100 galleries in the area offering every example of traditional Korean fine art from paintings to sculptures.

Special Thanks to Our Sponsors

PLATINUM



GOLD



BRONZE



NOTE



OEC 3D

Precise. Efficient.

S2K Healthcare 031-846-9333

STRENGTHEN BONES WITH PROLIA®

10년 간의 골절 위험 감소와 골밀도 증가를 입증한
프로리아®로 지속 치료해 주세요!¹⁻³



우수한 골밀도 증가 효과^{4,5}
주요 부위에서 BP 대비 우수한 골밀도
증가 효과를 보였습니다.



골절 위험 감소 효과³
10년까지 지속 치료 시 추가적인 척추 및
비척추 골절 감소 효과를 보였습니다.



BP, bisphosphonate.

References 1. Kendler DL, et al. *Adv Ther.* 2022;39(1):58-74. 2. Ferrari S, et al. *Bone.* 2020 May;134:115287. 3. Bone HG, et al. *Lancet Diabetes Endocrinol.* 2017;5(7):513-523. 4. Miller PD, et al. *J Clin Endocrinol Metab.* 2016;101(8):3163-70. 5. Kendler DL, et al. *J Bone Miner Res.* 2010;25(1):72-81.

Product Information

처방하시기 전 QR 코드 또는 식품의약품안전처 의약품통합정보시스템(<https://nedrug.mfds.go.kr>)을 통해 상세 제품정보를 참조하시기 바랍니다.



암젠코리아유한회사

서울특별시 중구 을지로5길 19, 20층 Tel. 02-3434-4899



종근당

공동판매원 종근당주식회사

서울특별시 서대문구 중정로 8 (충정로 37) TEL 02-2194-0300 FAX 02-2194-0369
소비자상담실 : 080-6776-080 (수신자부담) 제품상세정보 : www.ckdpharm.com 참조

ULTRACET®
with **SK chemicals**

**울트라셋® 제품요약정보¹**

트라이셋®정 (트라마돌염산염 37.5 mg, 아세트아미노펜 325 mg) 최근 변경일자: 2024-01-04

울트라셋® 이알서방정 (트라마돌염산염 75 mg, 아세트아미노펜 650 mg) 최근 변경일자: 2024-01-03

오트드리셋® 세미정 (트라마돌염산염 18.75 mg, 아세트아미노펜 162.5 mg) 최근 변경일자: 2024-01-04

울트라셋®이알세미서방정 (트라마돌염산염 37.5 mg, 아세트아미노펜 325 mg) 최근 변경일자: 2024-01-03

[illegible]

References 1. 울트라셋®정, 울트라셋®세미정, 울트라셋®이월사방정, 울트라셋®이월세미사방정, 제약품정보, 인악폴인전. Korea Available from: <https://nedrug.mfds.go.kr/>

【한국안센】 서울특별시 용산구 한강대로 92 (한강로 2가 LS용신타워 25층, 26층 04386 TEL.(02) 2094-4500 www.janssen.com/korea

[SK케미칼] 경기도 성남시 분당구 판교로 310(삼평동) TEL.(02) 2008-2008 www.skchemicals.com/ls

Better Sleep, Better Life

HEALSPINE

Heal your spine,


각 신체 부위에 최적화 된 4가지의 경도와 3가지의 탄성을 가진 하이브리드 폼으로

이상적인 **요추전만**과 **척추정렬**을 실현하는 힐스파인 매트리스는

세계에서 **허리가 가장 편안한 매트리스**를 지향합니다.



Comfort	Flex	Support	Balance	Support	Flex	Comfort
L-Zone 저탄성,저경도	H-Zone 고탄성,중저경도	M-Zone 중탄성,고경도	H-Zone 고탄성,중경도	M-Zone 중탄성,고경도	H-Zone 저탄성,중저경도	L-Zone 저탄성,저경도
(발) 체압 분산	(종아리) 체압 분산	(무릎) 근육 긴장 완화	(엉덩이,허벅지) 체형 유지, 체압 분산	(허리) 체압 분산	(어깨,등) 체형 유지, 체압 분산	(머리,목) 수면 시 진동을 흡수



OBODENCE[®] 60 mg

(Denosumab)

“**Verified** efficacy and safety
through clinical trials
involving Korean patients¹⁾”



**For detailed product information,
please scan the QR code.**

*For detailed information about the product, please refer to the product manual linked through the QR code which can also be viewed on the website (www.samsungbioepis.com/kr)

오보덴스® 프리필드시린지 60mg/1mL
Obodence Pre-filled syringe


¹⁾ Y.-S. CHUNG ET AL. BONE 192 (2025) 117371

[illegible]

C_KR_202504_025_250423

Powerful hemostasis with cross linked Hyaluronic acid

헤모펜스 헤모스태틱



팽창률 28%

세계 최초 가교히알루론산
매트릭스 지혈제



팽창률 28% 가교히알루론산 매트릭스

- ✓ 최대 28% 팽창하며 혈액 내 수분을 신속하게 흡수¹⁾
: 가교히알루론산 겔 팽윤도 300% - 1,500%^{2), 3), 4)}
- ✓ 가교화 히알루론산 유도체 매트릭스가 포함된 지혈 조성물 특허^{1), 2), 3), 4)}

5000 IU 고함량 트롬빈

- ✓ 젤라틴 매트릭스 지혈제 대비 2배 트롬빈 용량 함유⁵⁾
- ✓ 지혈 성공률 : 헤모펜스 97%, 젤라틴 매트릭스 96%⁶⁾
- ✓ 지혈 성공시간 : 헤모펜스 114.0초 vs 젤라틴 매트릭스 122.3초⁷⁾

Ref. 1) MFDS 허가 신청 자료, 2) 대한민국 공개특허 10-2018-0027126, 3) 미국/일본/러시아 특허 등록 정보, 4) In-house test, 5) 헤모펜스 헤모스태틱, 플로실 헤모스태틱 매트릭스 MFDS 허가, 6) 헤모펜스 허가용 임상 실험자 평가 지혈성공률, 7) 헤모펜스 허가용 임상 단회투여 첫번째 출혈부위 지혈시간

PYXIS®

3D printing
PLIF cage



Smooth Wedge-Shaped Design

: Easy Insertion

Minimized Sharp Edge


: Designed smooth edge
for minimizing damage

Bullet-tip Nose

: The nose designed easy to
rotational insertion

**Interconnected Irregular
Porous Structure**

: Irregular porous structure provide
optimized cellular adhesion and
proliferation



국내 최초의 Pregabalin 25mg, 50mg¹



Drug Information²

성분·함량

Pregabalin 25mg, 50mg, 75mg, 150mg, 300mg

효능·효과

1. 성인에서 말초와 중추 신경병증성 통증의 치료
2. 간질: 성인에서 이차적 전신증상을 동반하거나 동반하지 않은 부분 발작의 보조제
3. 섬유근육통의 치료

용법·용량

이 약은 프레가발린으로서 1일 총 투여용량을 1일 2회로 나누어 음식물과 상관 없이 경구 투여한다. 이 약은 주로 신장으로 배설되므로, 신기능이 저하된 환자에 대해서는 용량이 조절되어야 한다. 1. 신경병증성 통증 1) 말초 신경병증성 통증(성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 3일 내지 7일 후에 1일 300mg까지 증량할 수 있다. 필요하다면, 이후 7일 간격으로 1일 최대 600mg까지 증량할 수 있다. 2) 중추 신경병증성 통증(성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 1주일 후에 1일 300mg까지 증량할 수 있다. 추가로 1주일 후에 목표 1일 용량인 600mg까지 증량할 수 있다. 목표 1

일 용량에서 내약성을 나타내지 않을 경우 용량 감소가 고려될 수 있다. 2. 간질 (성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 일주일 후에 1일 300mg까지 증량할 수 있다. 필요하다면, 이후 7일 간격으로 1일 최대 600mg까지 증량할 수 있다. 3. 섬유근육통: 이 약의 권장 용량은 1일 300mg~450mg이다. 이 약은 시작 용량으로 75mg씩 1일 2회(1일 150mg)를 투여하며, 유효성과 내약성에 근거하여 1주일 이내에 150mg씩 1일 2회(1일 300mg)까지 증량할 수 있다. 1일 300mg의 용량에서 충분한 유익성을 경험하지 못한 환자의 경우에는 1주일 이내에 225mg씩 1일 2회(1일 450mg)까지 증량할 수 있다. 1일 600mg의 용량에서도 임상 연구가 실시되었으나, 이 용량에서의 부가적인 유익성이나 충분한 내약성에 대한 증거는 없다. 용량 의존적인 이상반응을 고려하면, 1일 450mg을 초과하는 용량 투여는 권장되지 않는다.

사용상의 주의사항

1. 경고 1) 자살충동과 자살행동 (1) 항간질약을 복용한 환자에서 자살충동 또는 자살행동을 보이는 위험성이 증가하므로 항간질약을 치료받은 환자는 자살충동 또는 자살행동, 우울증의 발현 또는 악화 및 기분과 행동의 비정상적 변화에 대하여 모니터링되어야 한다. (2) 항간질약을 처방받은 간질과 다른 많은 질병은

그 자체가 이환 및 사망, 치료기간 동안의 자살충동과 자살행동의 위험성증가와 관련된다. 따라서 처방자는 항간질약 처방시 환자의 치료기간 동안 자살충동 또는 자살행동과 치료될 질병간의 연관성 유무 및 이 약의 유효성을 함께 고려한다. 2. 다음 환자에는 투여하지 말 것 1) 프레가발린 또는 이 약의 성분에 과민한 환자 2) 이 약은 유당을 함유하고 있으므로, 갈락토오스 불내성 (galactose intolerance), Lapp 유당분해효소 결핍증 (Lapp lactase deficiency) 또는 포도당-갈락토오스 흡수 장애 (glucose-galactose malabsorption) 등의 유전적인 문제가 있는 환자에게는 투여하면 안 된다.

* 기타 자세한 사항은 제품설명서를 참고하십시오.

inno.N

에이치케이이노엔 주식회사


충청북도 청주시 흥덕구 오송읍 오송생명2로 239

서울 지사: 서울특별시 중구 을지로 100 파인에비뉴 6, 7, 8층

http://www.inno-n.com | Tel. 080-700-8802

CeLaPla


| Cervical Laminoplasty System |



Medyssey

TAURUS™

OBLIQUE LATERAL & ANTERIOR
INTERBODY FUSION CAGE



Medysey



연골보호효과 확인^{1,i}

장기투여 효과 확인^{1,2,ii}

안전성 프로파일 확인^{1,2}

제품요약정보³

전문의약품

【제품명】조인스정200mg 【원료약품 및 그 분량】이 약 1정 중 조인스정 유효성분: 위령선-팔루근-하고초30%에탄올건조엑스(40→1)(별규) ...200mg 【효능·효과】골관절증(퇴행관절질환), 류마티스관절염의 증상 완화 【용법·용량】성인 : 1회 1정을 1일 3회 경구투여한다. 증상에 따라 적절히 증감한다. 【사용상의 주의사항】1. 다음 환자에는 신중히 투여할 것. 1) 감염상태 또는 감염의 원인이 있는 환자(감염에 대한 자체 저항력이 감소될 가능성이 있음을 고려해야 하며, 이런 경우에는 감염의 진행을 억제하는 처치를 취해야 한다.) 2) 임부 또는 임신하고 있을 가능성이 있는 여성 및 수유부 (후략) 【제조사】에스케이케미칼(주) 충청북도 청주시 흥덕구 산단로 149 【판매자】에스케이케미칼(주) 경기도 성남시 분당구 판교로 310 2011. 3. 21. 개정


※처방하시기 전 제품설명서 전문을 참고하십시오. 최신 허가사항에 대한 정보는 '식품의약품 안전처 의약품안전나라 (<https://nedrug.mfds.go.kr/index>)'에서 확인할 수 있습니다.

References 1. Joong Il Kim et al, Efficacy of JOINS on Cartilage Protection in Knee Osteoarthritis: Prospective Randomized Controlled Trial, knee surg relat res. 2017 sep 1;29(3):217~224. 2. 조인스정 의약품 재심사 보고서 (2001.7.10~2005.7.9). Data on file SK 케미칼, [Updated 2005.10.07] 3. 조인스정 허가정보, 의약품안전나라 [Cited 2023.01.20] Available from: <https://nedrug.mfds.go.kr/>

i) [조인스정의 4상 임상연구] 1년(시험 연장 참여 동의자의 경우 2년)의 RCT 연구에서 무릎 골관절염 환자 76명을 대상으로 MRI를 이용하여 조인스정과 위약의 연골보호효과를 비교하였음.
ii) 조인스정의 4상 임상 결과 상 2년 장기투여 대상자를, 4년간의 시판후 조사결과 상 6개월 이상 장기투여(184명, 전체의 3.09%) 대상자 포함하였음.

Mirogabalin, your choice for Balanced Efficacy & Safety Profile¹⁻³

START SMART, TITRATE with CONFIDENCE



제품정보는 QR코드를
통해 확인하세요! 🔍



P25-018-2027.01-V1

Study design | 1. This study evaluated the efficacy and safety of mirogabalin, a novel, potent, selective ligand the $\alpha 2\delta$ subunit of voltage-dependent Ca^{2+} channels, for the treatment of diabetic peripheral neuropathic pain(DPNP). During this double-blind, multisite, placebo-controlled phase III study, Asian patients aged ≥ 20 years with type 1 or 2 diabetes and DPNP were randomized 2:1:1:1 to a placebo, mirogabalin 15, 20 or 30mg/day for up to 14 weeks, with a 1-to 2-week titration. The primary endpoint was the change from baseline in average daily pain score(ADPS) at week, defined as a weekly average of daily pain. 2. This study investigated the safety and efficacy of mirogabalin, a novel, potent, selective ligand of the $\alpha 2\delta$ subunit of voltage-dependent Ca channels, for the treatment of postherpetic neuralgia (PHN). In this multicenter, double-blind, placebo-controlled phase 3 study, Asian patients ≥ 20 years with PHN were randomized 2:1:1:1 to a placebo, mirogabalin 15, 20 or 30mg/day for up to 14 weeks. The primary efficacy endpoint was the change from baseline in average daily pain score at week 14, defined as a weekly average of daily pain. 3. This randomized, double-blind, multisite, placebo-controlled, phase 3 study investigated mirogabalin efficacy and safety for the treatment of central neuropathic pain in patients with traumatic spinal cord injury. Adult patients were randomized (1:1) to receive placebo or mirogabalin. The primary efficacy endpoint was change from baseline in the weekly average daily pain score (ADPS) at week 14.

Reference | 1. Baba, Masayuki et al. "Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients." Journal of diabetes investigation vol. 10,5 (2019) 2. Kato, Jitsu, et al. "Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients." Pain 160.5 (2019): 1175-1185. 3. Ushida, Takahiro, et al. "Mirogabalin for central neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled, phase 3 study in Asia." Neurology 100.11 (2023): e1193-e1206. 4. 탈리제® 허가사항 5. "탈리제 정제 이미지." 약학정보원

일회용 의료기기

재멸균 금지

재사용 금지

CollaStat®

Bioactive Collagen Hemostat



뛰어난 지혈작용

콜라겐 단백질 입자의 팽창으로 인한 물리적 압박과 트롬빈의 혈액응고 작용의 시너지 효과로 신속하고 효과적인 지혈이 가능하여 수술시간이 단축됩니다.



최소한의 조작

다림티센의 독자적인 트롬빈 안정화 기술로 트롬빈 용액을 준비하는 과정 없이 주사기를 결합하여 혼합하는 최소한의 조작만으로 사용 준비가 가능합니다.



적용의 편리성

Flowable한 제품으로 불규칙한 표면이나 접근이 어려운 부위에 적용이 가능합니다.

CollaStat®

품목명: 흡수성 체내용 지혈용품(4등급)

허가번호: 제허 16-518호

사용목적: 외과적 수술시 체내조직을 지혈

사용기한: 제조일로부터 2년

저장방법: 1°C - 25°C

용량: 3ml / 6ml

dalim (주)다림양행

판매원: (주)다림양행

서울시 마포구 월드컵북로 52-1

TEL. 02-335-1657

dalim (주)다림티센

제조원: (주)다림티센

서울시 마포구 연희로31 연남빌딩 3층-5층

TEL. 02-3142-0646

NovoStat

조직과의 밀착력을 높인 지혈용품

White layer



- 아테로콜라겐과 히알루론산 함유
- 다공성 구조로 혈액 및 삼출물 흡수

Yellow layer




- 트롬빈 함유
- 보조적인 지혈효과
- 레보도파 함유
- 조직과의 밀착력 증가

품목명	흡수성체내용지혈용품 / 4등급
주성분	Type 1 콜라겐, 히알루론산, 트롬빈, 레보도파
사용목적	외과적 수술 시 체내조직을 지혈하는데 사용하는 제품으로 흡수성 재료를 사용
사이즈	S size: 4.5cm × 6cm L size: 9cm × 6cm

골다공증 치료의 연속성을 위한 순차 치료는 대웅졸레드론산주사액 이 이어받겠습니다.

1년 1회 투여로 남녀 골다공증 치료
2년 1회 투여로 폐경 후 여성 골다공증 예방



대웅제약 **대웅졸레드론산 주사액**
Zoledronic acid 5mg / 100mL

Ref. > 1. 대웅졸레드론산주사액 5mg/100mL 제품설명서_식약처 허가사항.
2. Anastasilakis AD, et al. *Calcif Tissue Int.* 2024;113(4):469-473.

※ 본 의약품은 엄격한 품질관리를 위한 제품입니다. 만약 구입시 사용기한 또는 유효기간이 지났거나 변질, 변패, 오염되었거나 손상된 의약품은 공정거래위원회 고시(소비자 분쟁해결기준)에 의거, 구입한 약국 및 의약품 판매업자를 통해 교환 또는 환불받을 수 있습니다. ※ 의약품 사용 후 부작용 발생 시, 부작용 신고 및 피해구제 신청은 한국약물안전관리원에 할 수 있습니다. 【신청방법】 한국약물안전관리원 ☎ 1644-6223 (또는 14-3330), ☎ karp.drugsafe.or.kr | 대웅제약 소비자 센터 ☎ 080-550-8308-9(수신자 부담전화), 🌐 www.daewoong.co.kr 【신청대상】 의약품 부작용으로 사망, 장애, 질병 피해를 입은 환자 및 유족 【보상범위】 사망일시보상금, 장례비, 장애일시보상금, 진료비 ※ 자세한 제품 정보는 제품 설명서 및 QR 코드를 참조하시기 바랍니다.



국내 Bisphosphonate 경구제 허가약품 중 유일

주 1회, **식사와 관계없이 복용** 가능¹ Bisphosphonate

악토넬EC정 35mg

(Risedronate Sodium)

장용성 제형 & Chelating agent로

복용 Compliance



음식물과 상호작용



	악토넬 [®] EC정 35mg ³	악토넬 [®] 정 35mg ⁴	악토넬 [®] 정 150mg ⁵
성분·함량	리세드론산나트륨 35mg	리세드론산나트륨 35mg	리세드론산나트륨 150mg
효능·효과	폐경 후 여성의 골다공증 치료	1. 폐경 후 여성의 골다공증 치료와 예방 2. 남성의 골다공증 치료	폐경 후 여성의 골다공증 치료와 예방
용법·용량	주 1회 식사와 관계없이 경구투여	주 1회 경구투여 (아침식사 최소 30분 전에 복용하거나 또는 하루 중에 어떤 때라도 음식물이나 음료수의 섭취 전후로 최소 2시간 떨어져서 복용한다)	월 1회 경구투여 (충분한 흡수를 위해 하루 중 처음으로 음식물 또는 물 이외의 음료수를 섭취하기 최소 30분 전에 복용한다)
제품코드	644503330	644503310	644503320

Reference

1. 악토넬EC정 허가사항 (23.06월 기준, 의약품안전나라 의약품 정보 - 용법용량(성인) : 리세드론산나트륨으로서 1회 35mg을 주 1회 식사와 관계없이 아침에 경구 투여한다.) 2. McClung MR et al. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet, Osteoporosis Int. 2012 Jan;23(1):267-76. 3. 악토넬EC정 35mg 허가사항 (23년 11월 기준) 4. 악토넬정 35mg 허가사항 (23년 11월 기준) 5. 악토넬정 150mg 허가사항 (23년 11월 기준)


Medtronic

Infuse™ Bone Graft

Trusted. Proven. Predictable.



The Premium Product for Autograft Replacement with high osteoinductivity demonstrated safety and effectiveness in multiple clinical trials.



MFDS Official Indication (수허21-274호):

Single Level OLIF

(Oblique Lateral Interbody Fusion)

- Clydesdale™ Spinal System
- Pivox™ Oblique Lateral Spinal System

Single Level ALIF


(Anterior Lumbar Interbody Fusion)

- Perimeter™ Interbody Fusion Device
- Divergence-L™ Interbody Fusion Device


Medtronic

Infinity™ occipitocervical-upper thoracic system

Your trusted solution.
Because posterior
cervical should be easier.



이전에 없던
새로운 NSAID + 근이완제 복합제



에페신ACE 정

Eperisone 75mg + Aceclofenac 100mg

1st 발매 Eperisone + Aceclofenac 복합제 에페신ACE정

1st 제품 근이완제 1위 에페신SR정

1st 제약사 근이완제 전체 1위 명문제약

cf. UBIST data 2022년 처방조제액 기준

DRUG INFORMATION

【제품명】에페신에이스정 【보험코드】649808060 【보험약가】378원/정 【성분·함량】1정 중, 에페리손염산염 75mg, 아세클로페낙 100mg 【성상】흰색 내지 거의 흰색의 원형 서방성 필름코팅정
【효능·효과】근골격계 근육 연축 증상을 동반한 급성 요통 환자의 통증 완화 【용법·용량】○ 성인 : 1일 2회, 1회 1정 식후 경구 투여한다. 이 약은 분쇄하거나 분할 또는 씹지 않고 전체를 복용한다.
이상반응을 최소화하기 위하여 최단 기간 동안 투여해야 한다. ○ 간장애 환자 : 투여용량 감량이 필요한 간장애 환자 초기 치료 시, 이 약의 투여가 권장되지 않는다. ○ 고령자 : 고령자 중 투여용량의 감량이 필요한 경우에는, 이 약의 투여가 권장되지 않는다. 【저장방법】기밀용기, 실온보관(1~30℃) 【사용기간】제조일로부터 36개월 【포장단위】30정/병, 100정/병
* 자세한 사항은 제품설명서를 참조하세요.

치료제의 명가 -



명문제약(주)

Art of
Osteo**Ar**thritis therapy
The original diacerein **Art**rodar

골관절염 원인 치료제
ARTRODAR[®]
diacerein



아트로드나[®] 캡슐은
interleukin-1을 차단하여 골관절염의
원인을 치료해주는 **오리지널 Diacerein**으로
전 세계 29개국에서 판매되고 있습니다

원로공급
Manufactured under license of
TRB CHEMEDICA
Geneva-Switzerland

제조 · 판매원
치료제의 명가 -
명로제약(주)
www.mmpharm.co.kr

DRUG INFORMATION

명문아트로드나캡슐 50mg 보험코드 : 649801240 보험약가 : 212원/C 성분 · 함량 : Diacerein 50mg 성상 : 황갈색의 내용물이 들어있는 상부 - 황색, 하부 - 연황색의 경질 캡슐제
효능 · 효과 : 골(고관절, 슬관절)관절염 (관절증, 퇴행성 관절질환) 용법 · 용량 : 디아세레인으로서는 1일 50~100mg을 1~2회 분할하여 식후 경구투여 한다. 증상에 따라 적절히 증감한다.
명문아트로드나캡슐 25mg 보험코드 : 649801230 보험약가 : 124원/C 성분 · 함량 : Diacerein 25mg 성상 : 황갈색의 내용물이 들어있는 상부 - 주황색, 하부 - 흰색의 경질 캡슐제
효능 · 효과 : 골(고관절, 슬관절)관절염 (관절증, 퇴행성 관절질환) 용법 · 용량 : 디아세레인으로서는 1일 50~100mg을 1~2회 분할하여 식후 경구투여 한다. 증상에 따라 적절히 증감한다.

ARTRODA Cap. 25mg



ARTRODA Cap. 50mg



Baxter

Floseal

HEMOSTATIC MATRIX

OPERATION HERO


FAST & EASY TO USE^{1,2}



KO-AS19-210002

1. Floseal hemostatic matrix 국내 제품 설명서(식품의약품안전처
(<https://nedrug.mfds.go.kr>) 의약품등 제품정보장 참조)

2. Tackett, Scott M., et al. "Real-world outcomes of hemostatic matrices in cardiac surgery." Journal of cardiothoracic and vascular anesthesia 28,6 (2014): 1558-1565.




Choose OSTENE For Better Bone Healing

생체 적합성 뼈 지혈제

OSTENE은 수용성 외과 적용 물질로,¹

- 수술 시 뼈의 표면의 출혈을 조절하기 위해 국소적인 지혈작용을 합니다.¹
- 생화학적 작용이 아닌, 물리적인 보호막 제공합니다.¹
- 24-48시간 이내에 용해됨.²



- 마른 무균 장갑을 끼고 손가락으로 부드러운 상태가 되도록 성형해 줍니다.¹
- Ostene은 왁스(wax)보다는 껌(gum)또는 퍼티(putty)와 같이 다룰 수 있습니다.¹
- 활동 혹은 잠복 감염 부위에는 사용하지 않습니다.¹
- 뼈의 구조적 지지를 위해 사용하지 않습니다.¹

Reference

1. 흡수성체내용지혈용품 Ostene Bone Hemostasis Material 제품설명서
2. Wellisz T, Armstrong JK, Cambridge J, Fisher TC. Ostene, A New Water-Soluble Bone Hemostasis Agent. J Craniofac Surg. 2006;17:420-25.
3. 흡수성 뼈 지혈제 급여기준 보건복지부, 고시 제2017-152호, 2017.9.1. 시행

흡수성체내용지혈용품 [Ostene Bone Hemostasis Material] [사용목적] 수술 시 뼈의 출혈을 지혈하기 위하여 사용한다. 본 제품은 물리적 보호막을 제공함으로써 수술 시 뼈의 표면으로부터의 출혈을 조절하기 위해 국소적 지혈작용을 한다. 이 작용은 생화학적 작용이 아니다. **[사용시 주의사항]** 1. 본 제품은 일회용이므로 재사용 또는 재멸균하지 않는다. 2. 포장에 손상되어 멸균 손실이 있는 제품은 폐기한다. 3. 개봉한 제품은 사용하지 않았더라도 폐기한다. 포장용기의 밀봉이 깨지면 제품 오염의 위험 때문에 재사용할 수 없다. 4. 본 제품은 햇빛을 포함, 직사광선을 피하여 실온에 보관한다. 5. 활동 혹은 잠복 감염 부위에는 사용하지 않는다. 6. 뼈의 구조적 지지를 위해 사용하지 않는다. **[흡수성 뼈 지혈제 급여기준]** 1. 수용성 합성물질로 만들어진 뼈 지혈제는 BONE WAX에 비해 뼈 생성 및 골 융합 용이성, 뼈 감염을 방지하는 점 등을 감안하여 별도 산정하되, 만65세 이상의 흉골절개를 시행하는 심장수술에 한하여 사용량을 5g까지 인정함. 2. 상기 1항의 급여대상자의 다음의 경우에 사용하는 치료재료비용은 「선별급여 지정 및 실시 등에 관한 기준」에 따라 본인부담률을 80%로 적용함.

- 다음 -
가. 상기 1항의 만65세 이상의 흉골절개를 시행하는 심장수술에서 인정용량을 초과하여 사용한 경우 나. 만65세 미만의 흉골 절개를 시행하는 심장수술 다. 출혈이 많은 수술인 골반골절수술 라. 비구골절수술 마. 장관골의 관혈적정복술 바. 척추수술 사. 인공관절 삽입술

신경병증성 통증 1차 치료제 뉴론틴®¹

NEURONTIN

뉴론틴®은 신경병증성 통증에 1차 치료제 중 하나로 권고되었습니다.¹

References

1. Finnerup NB, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2): 162-73.
2. 뉴론틴® 정 제품설명서 개정년월일 2024.05.13 3. 뉴론틴® 캡슐 제품 설명서 개정년월일 2024.09.21

[수입자 / 판매자]  비아트리스 코리아(주)

[04527] 서울특별시 중구 세종대로 14, 비동 15층 (남대문로 52, 그랜드센트럴)
제품 의학정보 문의 Tel: 02-6411-6200 | E-mail: Viatriis-korea-MI@viatriis.com | Website: www.viatriis.co.kr

[판매자]  SK 케미칼

[13494] 경기도 성남시 분당구 판교로310 (삼평동)
제품 문의 Tel: 080-021-3131 | Website: www.skchemicals.com/ls



뉴론틴® 캡슐 제품 설명서



뉴론틴®정 제품 설명서



오직 환자를 위한 오리지널 프레가발린, 리리카

Original LYRICA의 가치

ONLY



신경병증성 통증 치료제 국내 처방량 부분 판매 1위¹

(UBIST D1 Sales 2022년 2월부터 2024년 1월까지 기준)



투여 1주차부터 나타난 위약 대비 유의한 통증감소 효과²

(리리카를 투여 받은 당뇨병성 말초신경병증성 통증 환자 기준)



다양한 국내/외 가이드라인³에서

신경병증성 통증 1차 치료제 중 하나로 권고된 리리카³⁻¹²



안전성 프로파일 확인¹³

* ONLY는 Original Lyrica의 약어입니다. * 단, 리리카® CR 서방정의 경우 말초 신경병증성 통증의 치료에 한합니다.¹⁴

¹Abbreviations: AAN, American Academy of Neurology; ADA, American Diabetes Association; CPS, Canadian Pain Society; EFNS, European Federation of Neurological Societies; ESMO, European Society for Medical Oncology; IASP, International Association for the Study of Pain; JSPC, Japan Society of Pain Clinicians; KSSS, Korean Society of Spine Surgery; NICE, National Institute for Health and Care Excellence; KDA, Korean Diabetes Association.

²References 1. UBIST D1 Sales (2022.02 ~ 2024.01) 2. R. Freeman, et al. Diabetes Care. 2008 Jul;31(7):1448-54. 3. 2010 EFNS Attal N, et al. 2010 revision. Eur J Neurol. 2010 Sep;17(9):1113-e88 4. 2011 KSSS: KJ Chung, et al. J Korean Soc Spine Surg 2011 Dec;18(4):246-253. 5. 2015 IASP: Finnerup NB, et al. Lancet Neurol. 2015 Feb;14(2):162-73. 6. 2018 JSPC: Sumitani M, et al. Journal of Anesthesia 2018;32:463-478. 7. 2017 CPS: D Moulin, et al. Pain Res Manag. Nov-Dec 2014;19(6):328-35. 8. 2018 ESMO: M Fallon, et al. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv166-iv191. 9. 2020 NICE: Brill V, et al. Neurology. 2011 May 17;76(20):1758-1765. 10. 2023 ADA: ElSayed NA, et al. Diabetes Care 2023;46(Suppl. 1):S203-S215. 11. 2021 AAN: Price R, et al. Neurology. 2022 Jan 4;98(1):31-43. 2021 12. 2023 당뇨병 진료지침 제8판 13. Freynhagen R, et al. Pain Practice. 2015;15(1):47-57. 14. 리리카® CR 서방정 제품설명서. 최종변경일자: 2025.3.18



국내 최초의 Pregabalin 25mg, 50mg¹



Drug Information²

성분 · 함량

Pregabalin 25mg, 50mg, 75mg, 150mg, 300mg

효능 · 효과

1. 성인에서 말초와 중추 신경병증성 통증의 치료
2. 간질: 성인에서 이차적 전신증상을 동반하거나 동반하지 않은 부분 발작의 보조제
3. 섬유근육통의 치료

용법 · 용량

이 약은 프레가발린으로서 1일 총 투여용량을 1일 2회로 나누어 음식물과 상관 없이 경구 투여한다. 이 약은 주로 신장으로 배설되므로, 신기능이 저하된 환자에 대해서는 용량이 조정되어야 한다. 1. 신경병증성 통증 1) 말초 신경병증성 통증(성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 3일 내지 7일 후에 1일 300mg까지 증량할 수 있다. 필요하다면, 이후 7일 간격으로 1일 최대 600mg까지 증량할 수 있다. 2) 중추 신경병증성 통증(성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 1주일 후에 1일 300mg까지 증량할 수 있다. 추가로 1주일 후에 목표 1일 용량인 600mg까지 증량할 수 있다. 목표 1

일 용량에서 내약성을 나타내지 않을 경우 용량 감소가 고려될 수 있다. 2. 간질 (성인): 이 약은 시작용량으로 1일 150mg을 투여할 수 있다. 개개 환자에서의 반응과 내약성에 근거하여 일주일 후에 1일 300mg까지 증량할 수 있다. 필요하다면, 이후 7일 간격으로 1일 최대 600mg까지 증량할 수 있다. 3. 섬유근육통: 이 약의 권장 용량은 1일 300mg~450mg이다. 이 약은 시작 용량으로 75mg씩 1일 2회(1일 150mg)를 투여하며, 유효성과 내약성에 근거하여 1주일 이내에 150mg씩 1일 2회(1일 300mg)까지 증량할 수 있다. 1일 300mg의 용량에서 충분한 유익성을 경험하지 못한 환자의 경우에는 1주일 이내에 225mg씩 1일 2회(1일 450mg)까지 증량할 수 있다. 1일 600mg의 용량에서도 임상 연구가 실시되었으나, 이 용량에서의 부가적인 유익성이나 충분한 내약성에 대한 증거는 없다. 용량 의존적인 이상반응을 고려하면, 1일 450mg을 초과하는 용량 투여는 권장되지 않는다.

사용상의 주의사항

1. 경고 1) 자살충동과 자살행동 (1) 항간질약을 복용한 환자에서 자살충동 또는 자살행동을 보이는 위험성이 증가하므로 항간질약을 치료받은 환자는 자살충동 또는 자살행동, 우울증의 발현 또는 악화 및 기분과 행동의 비정상적 변화에 대하여 모니터링되어야 한다. (2) 항간질약을 처방받은 간질과 다른 많은 질병은

그 자체가 이환 및 사망, 치료기간 동안의 자살충동과 자살행동의 위험성증가와 관련된다. 따라서 처방자는 항간질약 처방시 환자의 치료기간 동안 자살충동 또는 자살행동과 치료될 질병간의 연관성 유무 및 이 약의 유효성을 함께 고려한다. 2. 다음 환자에는 투여하지 말 것 1) 프레가발린 또는 이 약의 성분에 과민한 환자 2) 이 약은 유당을 함유하고 있으므로, 갈락토오스 불내성 (galactose intolerance), Lapp 유당분해효소 결핍증 (Lapp lactase deficiency) 또는 포도당-갈락토오스 흡수 장애 (glucose-galactose malabsorption) 등의 유전적인 문제가 있는 환자에게는 투여하면 안 된다.

* 기타 자세한 사항은 제품설명서를 참고하십시오.

inno.N

에이치케이이노엔 주식회사

충청북도 청주시 흥덕구 오송읍 오송생명2로 239

서울 지사: 서울특별시 중구 을지로 100 파인에비뉴 6, 7, 8층

<http://www.inno-n.com> | Tel. 080-700-8802




BMP-2, A NEW DIRECTION



NOVOSIS



rhBMP-2 + Hydroxyapatite



Release Slowly, Grow Perfectly




NOVOSIS is specifically designed to optimize the therapeutic efficacy and safety offering greater bone forming activity with more sustained and controlled-release of rhBMP-2(recombinant human bone morphogenetic protein-2) and specially designed Hydroxyapatite carrier(SLOREL™).

CGBIO CELL & GROWTH FACTOR
BIOTECHNOLOGY



Remodeling¹⁾ + Overflow Modeling¹⁾ Based Bone Formation



Daewon 대원제약

테로사 카트리지주 : [효능·효과] 1) 폐경기 이후 여성 및 골절의 위험이 높은 남성에 대한 골다공증의 치료 2) 골절의 위험이 높은 여성 및 남성에 있어서 지속적인 글루코코르티코이드 요법과 관련 된 골다공증의 치료 [용법·용량] 권장용량은 1일 1회 이 약 20 μ g을 대퇴부 또는 복부에 피하주사 한다. 환자들은 올바른 주사방법에 대하여 교육을 받아야 한다. 환자에게 펜의 정확한 사용을 지도하기 위한 사용자 안내서(user manual)도 있다. 이 약의 투약기간은 최대 24개월이다. 한 환자의 일생에서 이 약의 24개월 과정을 반복해서는 안 된다. 만일 음식섭취가 불충분한 경우에는, 환자들은 칼슘과 비타민D 보조제를 추가적으로 섭취하여야 한다. 이 약의 치료가 끝난 후에는, 환자들은 다른 골다공증 치료를 계속할 수 있다. [사용상의 주의사항] 다음 환자에는 투여하지 말 것. 1) 테리파라타이드 또는 이 약의 부형제 성분에 대하여 과민반응 2) 임부 및 수유부 3) 기존의 고칼슘혈증 4) 중증의 신장 기능손상 5) 일차적인 골다공증 이외에 대사성 골 질환 (부갑상선 기능항진증 및 뼈의 Paget's disease 포함) 6) 충분히 설명되지 않는 alkaline phosphatase 의 상승 7) 이전에 골격에 방사선 치료를 한 경우 8) 골격 악성종양 또는 골 전이가 있는 환자 * 이 외의 보다 자세한 사항은 테로사 카트리지주 제품설명서 전문을 참조하여 주시기를 바랍니다. [제조사] Richter-Helm BioLogics GmbH & Co.KG (Germany) (원료의약품), Gedeon Richter Plc, (Hungary) (완제의약품) [판매사] 대원제약(주) 서울특별시 성동구 천호대로 386 대표번호 : 02-2204-7000 소비자상담실 : 080-497-8272(수신자부담) <http://www.daewonpharm.com> Ref. 1, Dempster, D.W., Zhou, H., Ruff, V.A., Melby, T.E., Alam, J. and Taylor, K.A. (2018), J Bone Miner Res, 33: 627-633.

근골격계질환

Better option Better relief

신바로® / 펠루비® / 아티풀® / 보니센원스® / 테로사®





DBM S



MegaDBM S 제품은 탈회골기질(DBM:Demineralized Bone Matrix)과 골무기질 분말로 이루어진 혼합물에 히알루론산(HA)-카르복시메틸셀룰로오스(CMC)겔을 배합한 것으로, 골 결손이 발생한 부위를 채워주어 대체하며, 우수한 골유도능(osteinduction)과 골전도능(osteoconduction)을 보여줍니다.



Good osteoinductive
& Conductive potential



Physical integrity
& Superior Handling



Physical integrity
& Superior Handling



Ready to use

